Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2014 | 2-May-14 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Mar-14 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Trading Symbol | 'ISCO | ' |
Entity Registrant Name | 'International Stem Cell CORP | ' |
Entity Central Index Key | '0001355790 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 159,104,553 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (2014 Unaudited) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Assets | ' | ' |
Cash and cash equivalents | $991 | $2,243 |
Accounts receivable, net of allowance for doubtful accounts of $19 at March 31, 2014 and December 31, 2013 | 501 | 306 |
Inventory, net | 1,357 | 1,369 |
Prepaid expenses and other current assets | 636 | 658 |
Restricted cash | 50 | 50 |
Total current assets | 3,535 | 4,626 |
Property and equipment, net | 742 | 830 |
Intangible assets, net | 2,342 | 2,250 |
Deposits and other assets | 33 | 33 |
Total assets | 6,652 | 7,739 |
Liabilities, Redeemable Preferred Stock and Stockholders' Deficit | ' | ' |
Accounts payable | 518 | 532 |
Accrued liabilities | 952 | 1,290 |
Deferred revenue | 0 | 3 |
Related party payable | 26 | 21 |
Advances | 250 | 250 |
Fair value of warrant liability | 4,302 | 4,925 |
Total current liabilities | 6,048 | 7,021 |
Commitments and contingencies | ' | ' |
Stockholders' Deficit | ' | ' |
Common stock, $0.001 par value, 300,000,000 shares authorized, 156,904,553 and 151,175,053 issued and outstanding at March 31, 2014 and December 31, 2013, respectively | 157 | 151 |
Additional paid-in capital | 79,212 | 77,897 |
Accumulated deficit | -83,706 | -82,271 |
Total stockholders' deficit | -4,337 | -4,223 |
Total liabilities, redeemable preferred stock and stockholders' deficit | 6,652 | 7,739 |
Series G Preferred Stock [Member] | ' | ' |
Liabilities, Redeemable Preferred Stock and Stockholders' Deficit | ' | ' |
Convertible Redeemable Series G Preferred stock, $0.001 par value, 5,000,000 shares authorized, issued and outstanding at March 31, 2014 and December 31, 2013, liquidation preference of $5,000 at March 31, 2014 and December 31, 2013 | 4,941 | 4,941 |
Series D Preferred Stock [Member] | ' | ' |
Stockholders' Deficit | ' | ' |
Preferred stock | ' | ' |
Series B Preferred Stock [Member] | ' | ' |
Stockholders' Deficit | ' | ' |
Preferred stock | ' | ' |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (2014 Unaudited) (Parenthetical) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 30, 2008 | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | Series G Preferred Stock [Member] | Series G Preferred Stock [Member] | Series D Preferred Stock [Member] | Series D Preferred Stock [Member] | Series D Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | ||
Allowance for doubtful accounts receivable | $19 | $19 | ' | ' | ' | ' | ' | ' | ' |
Convertible Redeemable Preferred stock, par value | ' | ' | $0.00 | $0.00 | ' | ' | ' | ' | ' |
Convertible Redeemable Preferred stock, shares authorized | ' | ' | 5,000,000 | 5,000,000 | ' | ' | ' | ' | ' |
Convertible Redeemable Preferred stock, shares issued | ' | ' | 5,000,000 | 5,000,000 | ' | ' | ' | ' | ' |
Convertible Redeemable Preferred stock, shares outstanding | ' | ' | 5,000,000 | 5,000,000 | ' | ' | ' | ' | ' |
Convertible Redeemable Preferred stock, liquidation preference | ' | ' | $5,000 | $5,000 | ' | ' | ' | ' | ' |
Preferred stock, par value | $0.00 | ' | ' | ' | $0.00 | $0.00 | ' | $0.00 | $0.00 |
Preferred stock, shares authorized | 20,000,000 | ' | ' | ' | 50 | 50 | ' | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | ' | ' | 5,000,000 | 5,000,000 | 43 | 43 | 43 | 300,000 | 300,000 |
Preferred stock, shares outstanding | ' | ' | 5,000,000 | 5,000,000 | 43 | 43 | ' | 300,000 | 300,000 |
Liquidation preference | ' | ' | ' | ' | $4,320 | $4,320 | ' | $408 | $403 |
Common stock, par value | $0.00 | $0.00 | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares authorized | 300,000,000 | 300,000,000 | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares issued | 156,904,553 | 151,175,053 | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares outstanding | 156,904,553 | 151,175,053 | ' | ' | ' | ' | ' | ' | ' |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations (Unaudited) (USD $) | 3 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Revenues | ' | ' |
Product sales | $1,649 | $1,285 |
Total revenue | 1,649 | 1,285 |
Expenses | ' | ' |
Cost of sales | 439 | 334 |
Research and development | 958 | 721 |
Selling and marketing | 669 | 511 |
General and administrative | 1,648 | 1,432 |
Total expenses | 3,714 | 2,998 |
Loss from operating activities | -2,065 | -1,713 |
Other income (expense) | ' | ' |
Change in fair value of warrant liability | 623 | ' |
Miscellaneous expense | ' | -2 |
Interest expense | -1 | -1 |
Sublease income | 8 | 4 |
Total other income (expense), net | 630 | 1 |
Loss before income taxes | -1,435 | -1,712 |
Provision for income taxes | ' | ' |
Net loss | -1,435 | -1,712 |
Net loss applicable to common stockholders | ($1,435) | ($1,712) |
Net loss per common share-basic and diluted | ($0.01) | ($0.02) |
Weighted average shares-basic and diluted | 153,488 | 103,566 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit (2014 Unaudited) (USD $) | Total | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Convertible Redeemable Preferred Stock [Member] | Common Stock [Member] | Convertible Preferred Stock [Member] | Convertible Preferred Stock [Member] | Convertible Preferred Stock [Member] |
In Thousands | Series G Preferred Stock [Member] | Series B Preferred Stock [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | ||||
Beginning balance at Dec. 31, 2012 | ($1,758) | $69,945 | ($71,792) | $4,941 | $87 | ' | $2 | ' |
Beginning balance, shares at Dec. 31, 2012 | ' | ' | ' | 5,000 | 87,389 | 300 | 2,000 | ' |
Issuance of common stock from conversion of Series C preferred stock | ' | -6 | ' | ' | 8 | ' | -2 | ' |
Issuance of common stock from conversion of Series C preferred stock, shares | ' | ' | ' | ' | 8,000 | ' | -2,000 | ' |
Issuance of common stock | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' |
For cash, net of issuance costs of $178 in 2013 and $169 in 2014 | 3,381 | 3,343 | ' | ' | 38 | ' | ' | ' |
For cash, net of issuance costs of $178 in 2013 and $169 in 2014, shares | ' | ' | ' | ' | 37,991 | ' | ' | ' |
For services | 240 | 239 | ' | ' | 1 | ' | ' | ' |
For services, shares | ' | ' | ' | ' | 840 | ' | ' | ' |
From exercises of warrants, net of commissions of $98 | 2,700 | 2,683 | ' | ' | 17 | ' | ' | ' |
From exercises of warrants, net of commissions of $98, shares | ' | ' | ' | ' | 16,955 | ' | ' | ' |
Stock-based compensation | 1,693 | 1,693 | ' | ' | ' | ' | ' | ' |
Net loss | -10,479 | ' | -10,479 | ' | ' | ' | ' | ' |
Ending balance at Dec. 31, 2013 | -4,223 | 77,897 | -82,271 | 4,941 | 151 | ' | ' | ' |
Ending balance, shares at Dec. 31, 2013 | ' | ' | ' | 5,000 | 151,175 | 300 | ' | ' |
Issuance of common stock | ' | ' | ' | ' | ' | ' | ' | ' |
For cash, net of issuance costs of $178 in 2013 and $169 in 2014 | 935 | 930 | ' | ' | 5 | ' | ' | ' |
For cash, net of issuance costs of $178 in 2013 and $169 in 2014, shares | ' | ' | ' | ' | 5,200 | ' | ' | ' |
For services | 39 | 38 | ' | ' | 1 | ' | ' | ' |
For services, shares | ' | ' | ' | ' | 530 | ' | ' | ' |
Stock-based compensation | 347 | 347 | ' | ' | ' | ' | ' | ' |
Net loss | -1,435 | ' | -1,435 | ' | ' | ' | ' | ' |
Ending balance at Mar. 31, 2014 | ($4,337) | $79,212 | ($83,706) | $4,941 | $157 | ' | ' | ' |
Ending balance, shares at Mar. 31, 2014 | ' | ' | ' | 5,000 | 156,905 | 300 | ' | ' |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit (2014 Unaudited) (Parenthetical) (USD $) | 3 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 |
Statement Of Stockholders Equity [Abstract] | ' | ' |
For cash, issuance costs | $169 | $178 |
From exercise of warrants, commissions | ' | $98 |
Condensed_Consolidated_Stateme3
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Cash flows from operating activities | ' | ' |
Net loss | ($1,435) | ($1,712) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 116 | 116 |
Stock-based compensation expense | 347 | 409 |
Common stock issued for services | 39 | 68 |
Change in fair value of warrant liability | -623 | ' |
Allowance for inventory obsolescence | 4 | 4 |
Impairment of intangible assets | 36 | 19 |
Changes in operating assets and liabilities | ' | ' |
(Increase) decrease in accounts receivable | -195 | -111 |
(Increase) decrease in inventory | 8 | -11 |
(Increase) decrease in prepaid assets and other assets | 22 | -36 |
Increase (decrease) in accounts payable | -14 | -539 |
Increase (decrease) in accrued liabilities | -338 | 16 |
Increase (decrease) in deferred revenue | -3 | -70 |
Increase (decrease) in related party payable | 5 | ' |
Net cash used in operating activities | -2,031 | -1,847 |
Investing activities | ' | ' |
Purchases of property and equipment | -13 | ' |
Payments for patent licenses and trademarks | -143 | -168 |
Net cash used in investing activities | -156 | -168 |
Financing activities | ' | ' |
Proceeds from issuance of common stock | 1,104 | 3,289 |
Payment of offering costs | -169 | -16 |
Net cash provided by financing activities | 935 | 3,273 |
Net increase (decrease) in cash and cash equivalents | -1,252 | 1,258 |
Cash and cash equivalents, beginning of period | 2,243 | 654 |
Cash and cash equivalents, end of period | 991 | 1,912 |
Supplemental disclosure of cash flow information | ' | ' |
Cash paid for interest | $1 | $1 |
Organization_and_Significant_A
Organization and Significant Accounting Policies | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Organization and Significant Accounting Policies | ' | ||||||||||||||||
1. Organization and Significant Accounting Policies | |||||||||||||||||
Business Combination and Corporate Restructure | |||||||||||||||||
BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now the wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation. | |||||||||||||||||
Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval. | |||||||||||||||||
On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 20,000,000 shares of ISC California Common Stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California. | |||||||||||||||||
Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmeceutical products, utilizing an extract derived from the Company’s human parthenogenetic stem cell technologies. | |||||||||||||||||
Going Concern | |||||||||||||||||
The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $677,000 per month, excluding capital expenditures and patent costs averaging $52,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow, and that such cash flows will be sufficient to sustain the Company’s operations through 2014. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company is a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. | |||||||||||||||||
Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. In December 2013, the Company filed a registration statement with the SEC, which allows the Company to sell up to $10,250,000 of common stock to Lincoln Park Capital Fund, LLC (“Lincoln Park”) from time to time through January 2017 at the Company’s discretion. The registration statement was declared effective on January 13, 2014. However, the Company cannot predict the timing or amount of any funds that it may actually receive. During the first quarter of 2014, to obtain funding for working capital purposes, the Company sold a total of 5,200,000 shares of common stock under the stock Purchase Agreement with Lincoln Park, raising approximately $1,104,000. For further discussion, see Note 6, Capital Stock. Subsequent to March 31, 2014 through to May 2, 2014, the Company has sold an additional 2,200,000 shares of common stock under this stock Purchase Agreement, for an aggregate of approximately $360,000, as discussed in Note 12, Subsequent Events. | |||||||||||||||||
Basis of Presentation | |||||||||||||||||
The Company is a biotechnology company focused on therapeutic and clinical product development with multiple long-term therapeutic opportunities and two revenue-generating subsidiaries with potential for increased future revenues. The Company was in the development stage from inception through the quarter ended September 30, 2013. During the quarter ended December 31, 2013, the Company exited the development stage based on a consistent, increasing revenue trend and more significant revenue generated from its two commercial businesses. The Company generated product revenues from the two commercial businesses of $6,147,000 for the year ended December 31, 2013. The Company currently has no revenue generated from its principal operations in therapeutic and clinical product development through research and development efforts. | |||||||||||||||||
The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. | |||||||||||||||||
These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2013. When used in these notes, the terms “Company,” “we,” “us,” or “our” mean International Stem Cell Corporation and all entities included in the unaudited condensed consolidated financial statements. | |||||||||||||||||
In the opinion of management, the unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2013 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year. | |||||||||||||||||
Principles of Consolidation | |||||||||||||||||
The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated. | |||||||||||||||||
Reclassification | |||||||||||||||||
Certain amounts within the unaudited condensed consolidated statements of operations for the prior period have been reclassified to conform to the current period presentation. These reclassifications had no impact on the Company’s previously reported results of operations. | |||||||||||||||||
Cash Equivalents | |||||||||||||||||
The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. | |||||||||||||||||
Restricted Cash | |||||||||||||||||
The Company is required to maintain $50,000 in a restricted certificate of deposit account in order to fully collateralize two revolving credit card accounts. | |||||||||||||||||
Inventories | |||||||||||||||||
Inventories are accounted for using the first-in, first-out (FIFO) method for LSC products, and specific identification method for LCT products. Inventory balances are stated at the lower of cost or market. Laboratory supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly. | |||||||||||||||||
Accounts Receivable | |||||||||||||||||
Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of March 31, 2014 and December 31, 2013, the Company had an allowance for bad debt totaling $19,000. | |||||||||||||||||
Property and Equipment | |||||||||||||||||
Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset. | |||||||||||||||||
Intangible Assets | |||||||||||||||||
Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and patent licenses were recorded at cost of $2,867,000 and $2,760,000 at March 31, 2014 and December 31, 2013, respectively, and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license. Amortization expense for the three months ended March 31, 2014 and 2013 amounted to $15,000, and is included in research and development expense. Accumulated amortization as of March 31, 2014 and December 31, 2013 was $525,000 and $510,000, respectively. Additional information regarding patents and patent licenses is included in Note 4. | |||||||||||||||||
Long-Lived Asset Impairment | |||||||||||||||||
The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company did not recognize material impairments on its long-lived assets during the three months ended March 31, 2014 and 2013. | |||||||||||||||||
Product Sales | |||||||||||||||||
The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has lapsed. LCT contributed 51% and 49% of total revenue during the three months ended March 31, 2014 and 2013, respectively. LSC contributed 49% and 51% of total revenue during the three months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Deferred Revenue and Allowance for Sales Returns | |||||||||||||||||
The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee to be approximately 3% for the years ended December 31, 2013 and 2012. At March 31, 2014 and December 31, 2013, the estimated allowance for sales returns was $10,000. At March 31, 2014 and December 31, 2013, net deferred revenue totaled $0 and $3,000, respectively. | |||||||||||||||||
Cost of Sales | |||||||||||||||||
Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future. | |||||||||||||||||
Research and Development Costs | |||||||||||||||||
Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses. | |||||||||||||||||
Stock-Based Compensation | |||||||||||||||||
The Company recognized stock-based compensation expense associated with stock options and other stock-based awards in accordance with the authoritative guidance for stock-based compensation. The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award, and is recognized as expense on a straight-line basis, net of estimated forfeitures over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The fair value of restricted stock awards is based on the market value of our common stock on the date of grant. | |||||||||||||||||
Fair Value Measurements | |||||||||||||||||
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: | |||||||||||||||||
Level 1 | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; | ||||||||||||||||
Level 2 | Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and | ||||||||||||||||
Level 3 | Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). | ||||||||||||||||
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. | |||||||||||||||||
The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of March 31, 2014 (in thousands): | |||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||
ASSETS: | |||||||||||||||||
Cash equivalents | $ | 5 | $ | 5 | $ | — | $ | — | |||||||||
LIABILITIES: | |||||||||||||||||
Warrants to purchase common stock | $ | 4,302 | $ | — | $ | — | $ | 4,302 | |||||||||
The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2013 (in thousands): | |||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||
ASSETS: | |||||||||||||||||
Cash equivalents | $ | 5 | $ | 5 | $ | — | $ | — | |||||||||
LIABILITIES: | |||||||||||||||||
Warrants to purchase common stock | $ | 4,925 | $ | — | $ | — | $ | 4,925 | |||||||||
The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands): | |||||||||||||||||
Warrants to purchase | |||||||||||||||||
common stock | |||||||||||||||||
Beginning balance at December 31, 2012 | $ | — | |||||||||||||||
Issuances of warrants | 5,986 | ||||||||||||||||
Exercise of warrants | (1,815 | ) | |||||||||||||||
Adjustments to estimated fair value | 754 | ||||||||||||||||
Ending balance at December 31, 2013 | 4,925 | ||||||||||||||||
Issuances of warrants | — | ||||||||||||||||
Exercise of warrants | — | ||||||||||||||||
Adjustments to estimated fair value | (623 | ) | |||||||||||||||
Ending balance at March 31, 2014 | $ | 4,302 | |||||||||||||||
Income Taxes | |||||||||||||||||
The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. | |||||||||||||||||
Use of Estimates | |||||||||||||||||
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates. | |||||||||||||||||
Fair Value of Financial Instruments | |||||||||||||||||
The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of March 31, 2014 and December 31, 2013 approximate their fair values because of the short-term nature of those instruments. The fair value of certain warrants is determined at each quarterly reporting date as necessary using the Monte-Carlo valuation methodology. | |||||||||||||||||
Income (Loss) Per Common Share | |||||||||||||||||
The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At March 31, 2014, there were 552,625 non-vested restricted stock awards, 19,431,138 vested and 3,848,655 non-vested stock options outstanding, and 44,983,988 warrants outstanding, which were convertible into 45,650,654 shares of common stock; and at March 31, 2013, there were 822,500 non-vested restricted stock awards, 15,864,448 vested and 6,811,745 non-vested stock options outstanding, and 9,462,500 warrants outstanding, which were convertible into 9,462,500 shares of common stock. These restricted stock awards, stock options and warrants were not included in the diluted loss per share calculation because the effect would have been anti-dilutive. | |||||||||||||||||
Comprehensive Income | |||||||||||||||||
Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net loss from operations for the three months ended March 31, 2014 and 2013. | |||||||||||||||||
Registration Payment Arrangements | |||||||||||||||||
In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities. | |||||||||||||||||
Recent Accounting Pronouncements | |||||||||||||||||
In July 2013, the FASB issued an accounting standards update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company has adopted this guidance at the beginning of the first quarter of fiscal year 2014. The adoption of this standard does not have a material impact on the Company’s financial position, results of operations or related financial statement disclosures. |
Inventory
Inventory | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventory | ' | ||||||||
2. Inventory | |||||||||
The components of inventories are as follows (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 178 | $ | 147 | |||||
Work in process | 397 | 446 | |||||||
Finished goods | 912 | 902 | |||||||
Total | 1,487 | 1,495 | |||||||
Less: allowance for inventory obsolescence | (130 | ) | (126 | ) | |||||
Inventory, net | $ | 1,357 | $ | 1,369 | |||||
Property_and_Equipment
Property and Equipment | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Property Plant And Equipment [Abstract] | ' | ||||||||
Property and Equipment | ' | ||||||||
3. Property and Equipment | |||||||||
Property and equipment consists of the following (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
Machinery and equipment | $ | 1,178 | $ | 1,170 | |||||
Computer equipment | 249 | 246 | |||||||
Office equipment | 205 | 203 | |||||||
Leasehold improvements | 745 | 745 | |||||||
2,377 | 2,364 | ||||||||
Less: accumulated depreciation and amortization | (1,635 | ) | (1,534 | ) | |||||
Property and equipment, net | $ | 742 | $ | 830 | |||||
Depreciation expenses for the three months ended March 31, 2014 and 2013 were $101,000. |
Patent_Licenses
Patent Licenses | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Goodwill And Intangible Assets Disclosure [Abstract] | ' | ||||
Patent Licenses | ' | ||||
4. Patent Licenses | |||||
On December 31, 2003, LCT entered into an Option to License Intellectual Property agreement with Advanced Cell Technology, Inc. (“ACT”) for patent rights and paid ACT $340,000 in option and license fees. On February 13, 2004, LCT and ACT amended the Option agreement and LCT paid ACT additional option fees of $22,500 for fees related to registering ACT’s patents in selected international countries. | |||||
On May 14, 2004, LCT amended the licensing agreement with ACT for the exclusive worldwide patent rights for the following ACT technologies: UMass IP, ACT IP and Infigen IP. The additional license fees paid were $400,000. | |||||
On February 7, 2013, the Company and ACT entered into Amended and Restated License Agreements (the “Amendment”) for the purpose of completely amending and restating the terms of the license agreements. Under the terms of the Amendment, the Company acquired exclusive world-wide rights to all human therapeutic uses and cosmetic uses from ATC and Infigen’s early work on parthenogenic-derived embryonic stem cells, as well as certain rights to patents covering Single Blastomere technology. | |||||
Pursuant to the Amendment, all minimum R&D requirements and all milestone payments due to ACT under the Exclusive License Agreement have been eliminated. The Company will no longer pay any royalties under the ACT IP Agreement and Infigen IP Agreement. The obligation to pay royalties that ranged from 6%-12% under the UMass IP Agreement has been reduced to 0.25% of the net sales of products using technology covered by the UMass IP Agreement; and the obligation to pay a minimum annual license fee of $150,000 has been reduced to $75,000 annually, payable in two installments to ACT. | |||||
As of March 31, 2014, the total amount capitalized related to the acquired ACT licenses was $747,000, and $2,078,000 related to the other patent acquisition costs. | |||||
At March 31, 2014, future amortization expense related to intangible assets subject to amortization is expected to be as follows (in thousands): | |||||
Amount | |||||
2014 (remaining nine months) | $ | 48 | |||
2015 | 63 | ||||
2016 | 64 | ||||
2017 | 64 | ||||
2018 | 64 | ||||
Thereafter | 2,018 | ||||
Total | $ | 2,321 | |||
Advances
Advances | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Text Block [Abstract] | ' | ||||||||
Advances | ' | ||||||||
5. Advances | |||||||||
On June 18, 2008, the Company entered into an agreement with BioTime, Inc. (“Bio Time”), where Bio Time will pay an advance of $250,000 to LCT to produce, make, and distribute Joint Products. The $250,000 advance will be paid down with the first $250,000 of net revenues that otherwise would be allocated to LCT under the agreement. As of March 31, 2014 no revenues were realized from this agreement. | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
BioTime, Inc. (in thousands) | $ | 250 | $ | 250 |
Capital_Stock
Capital Stock | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Equity [Abstract] | ' | ||||
Capital Stock | ' | ||||
6. Capital Stock | |||||
As of March 31, 2014, the Company is authorized to issue 300,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share. | |||||
Preferred Stock Transactions | |||||
Series B Preferred Stock | |||||
On May 12, 2008, to obtain funding for working capital, the Company entered into a series of subscription agreements with five accredited investors for the sale of a total of 400,000 Series B Units, each Series B Unit consisting of one share of Series B Preferred Stock (“Series B Preferred”) and two Series B Warrants (“Series B Warrants”) to purchase common stock for each $1.00 invested. | |||||
The total purchase price received by the Company was $400,000. The Series B Preferred is convertible into shares of common stock at the initial conversion ratio of two shares of common stock for each share of Series B Preferred converted (which was established based on an initial conversion price of $0.50 per share), and the Series B Warrants were exercisable at $0.50 per share until five years from the issuance of the Series B Warrants, which expired unexercised in May 2013. The Series B Preferred contain anti-dilution clauses whereby, if the Company issues equity securities or securities convertible into equity at a price below the conversion price of the Series B Preferred, such conversion price shall be adjusted downward to equal the price of the new securities. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price of the Series B Preferred to $0.20. As a result of the 2013 S-1July Registered Offering discussed below, the conversion price for the Series B Preferred was reduced to $0.15 and $0.1452 in the third and fourth quarters of 2013, respectively. The Series B Preferred has a priority (senior to the shares of common stock) on any sale or liquidation of the Company equal to the purchase price of the Series B Units, plus a liquidation premium of 6% per year. If the Company elects to declare a dividend in any year, it must first pay to the Series B Preferred holder a dividend equal to the amount of the dividend the Series B Preferred holder would receive if the Series B Preferred were converted just prior to the dividend declaration. Each share of Series B Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As of March 31, 2014 and December 31, 2013, there were 300,000 shares of the Series B Preferred issued and outstanding. | |||||
Series C Preferred Stock | |||||
On August 20, 2008, 700,000 shares of Series C Preferred Stock (“Series C Preferred”) were sold, and 1,300,000 shares of Series C Preferred were sold on September 23, 2008 all at a price of $1.00 per Series C Preferred share. The Series C Preferred was convertible into shares of common stock at $0.25 per share. All the Series C Preferred was issued to X-Master Inc., which is a related party and affiliated with the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors Dr. Andrey Semechkin and Dr. Ruslan Semechkin, Chief Scientific Officer of International Stem Cell and a director. | |||||
As of March 31, 2014 and December 31, 2013, there were 0 shares of the Series C Preferred issued and outstanding. On January 22, 2013, the holders of Series C Preferred converted all of the outstanding shares of Series C Preferred into common stock at $0.25 per share, or a total of 8,000,000 shares of common stock. | |||||
On April 10, 2013, the Company filed a Certificate of Elimination for the Series C Preferred stock. The Certificate of Elimination amended the provisions of the Certificate of Incorporation of the Company to eliminate the powers, designations, preferences, privileges and other rights of the Series C Preferred stock. | |||||
Series D Preferred Stock | |||||
On December 30, 2008, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Agreement”) with accredited investors (the “Investors”) and sold 43 shares of Series D Preferred Stock (“Series D Preferred”) for total proceeds of $4,700,000 at a price of $100,000 per Series D Preferred share. | |||||
10 shares of the Series D Preferred were issued to X-Master Inc., which is a related party and affiliated with the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin and Dr. Ruslan Semechkin, Chief Scientific Officer and a director; and 33 shares of the Series D Preferred were issued to Dr. Andrey Semechkin. As of March 31, 2014 and December 31, 2013, there were 43 shares of the Series D Preferred issued and outstanding. | |||||
On December 4, 2012, the holders of all of the outstanding shares of Series D Preferred executed a Waiver of Anti-Dilution Rights (the “Anti-Dilution Waiver”) pursuant to which such holders waived all anti-dilution adjustment rights under the Certificate of Designation for the Series D Preferred in connection with the offering of securities pursuant to the registration statement originally filed with the SEC on October 18, 2012, including the shares issuable on exercise of all warrants registered thereunder. The Anti-Dilution Waiver applied to the financing transaction that closed on July 24, 2013. The Anti-Dilution Waiver does not apply to any future issuances of securities which would otherwise trigger anti-dilution adjustments under the Certificate of Designation for the Series D Preferred. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price of the Series D Preferred to $0.20. During December 2013, the Company issued additional shares of common stock at $0.15 per share, triggering an adjustment in the current conversion price of the Series D Preferred to $0.15 per share. | |||||
Series G Preferred Stock | |||||
On March 9, 2012, the Company entered into a Series G Preferred Stock Purchase Agreement (the “Series G Agreement”) with AR Partners, LLC (the “Purchaser”) to sell 5,000,000 shares of Series G Preferred Stock (“Series G Preferred”) at a price of $1.00 per Series G Preferred share, for a total purchase price of $5,000,000. The Purchaser is an affiliate of Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, and Dr. Ruslan Semechkin, Chief Scientific Officer and a director. | |||||
The Series G Preferred was initially convertible into shares of common stock at $0.40 per share, resulting in an initial conversion ratio of 2.5 shares of common stock for every share of Series G Preferred. The conversion price may be adjusted for stock splits and other combinations, dividends and distributions, recapitalizations and reclassifications, exchanges or substitutions and is subject to a weighted-average adjustment in the event of the issuance of additional shares of common stock below the conversion price. | |||||
The Series G Preferred shares have priority over the Series B Preferred and common stock on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of the Series G Preferred, but such payment may be made only after payment in full of the liquidation preferences payable to holders of any shares of Series D Preferred then outstanding. Each share of Series G Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As long as there are at least 1,000,000 shares of Series G Preferred outstanding, the holders of Series G Preferred have (i) the initial right to propose the nomination of two members of the Board, at least one of which such nominees shall be subject to the approval of the Company’s independent directors, for election by the stockholder’s at the Company’s next annual meeting of stockholders, or, elected by the full board of directors to fill a vacancy, as the case may be, and (ii) the right to approve any amendment to the certificate of incorporation, certificates of designation or bylaws, in manner adverse to the Series G Preferred, alter the percentage of board seats held by the Series G Preferred directors or increase the authorized number of shares of Series G Preferred. At least one of the two directors nominated by holders of the Series G Preferred shall be independent based on the NASDAQ listing requirements. | |||||
The Company determined that the Series G Preferred have a contingent redemption feature allowing redemption by the holder under only some very limited circumstances (“deemed liquidation events”). As the event that may trigger the redemption of the convertible preferred stock is not solely within the Company’s control, the convertible preferred stock has been classified as mezzanine equity (outside of permanent equity) on the Company’s consolidated balance sheet. Additionally, legal costs related to the Series G Preferred financing in the amount of $59,000 were recorded in the mezzanine equity as well. | |||||
As of March 31, 2014 and December 31, 2013, there were 5,000,000 shares of the Series G Preferred issued and outstanding. | |||||
During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price and the conversion ratio of the Series G Preferred to $0.37 per share and 2.67 shares, respectively. As a result of the 2013 S-1 July Registered Offering during the third quarter of 2013, the conversion price and the conversion ratio for the Series G Preferred were adjusted to $0.30 per share and 3.28 shares, respectively. During December 2013, the Company issued additional shares of common stock at $0.15 per share, triggering an adjustment in the conversion price and the conversion ratio for the Series G Preferred to $0.3039 per share and 3.291 shares, respectively. | |||||
During the first quarter of 2014, the Company issued additional shares of common stock, under the stock Purchase Agreement with Lincoln Park, at various prices ranging from $0.175 to $0.223 per share, triggering numerous adjustments in the conversion price and the conversion ratio of the Series G Preferred. As of March 31, 2014, the adjusted conversion price and the conversion ratio were $0.3021 per share and 3.310 shares, respectively. | |||||
Common Stock Transactions | |||||
2013 Securities Purchase Agreements for Common Stock | |||||
On January 22, 2013, to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with Dr. Andrey Semechkin and Dr. Simon Craw to sell a total of 10,125,000 shares of common stock at a price of $0.20 per share, for a total purchase price of $2,025,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer. Dr. Simon Craw is the Company’s Executive Vice President Business Development. The sale of the shares of common stock was completed on January 22, 2013. In connection with the sale of these shares the Company issued to each purchaser a warrant, exercisable for a period of 5 years, to purchase a number of shares of common stock equal to 50% of the shares purchased by that purchaser, for a total of 5,062,500 shares subject to the warrants at an exercise price of $0.20 per share. | |||||
On March 12, 2013, to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with certain investors, including Dr. Andrey Semechkin, to sell a total of 5,000,000 shares of common stock at a price of $0.20 per share, for a total purchase price of $1,000,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer and purchased $100,000 worth of common stock. Each of the other investors has had a long-standing relationship with the Company and has closely followed the Company. The sale of the shares of common stock was completed on March 12, 2013. In connection with the sale of these shares the Company issued to each investor a warrant, exercisable for a period of five years, to purchase a number of shares of common stock equal to 50% of the shares purchased by that investor, for a total of 2,500,000 shares subject to the warrants at an exercise price of $0.20 per share. | |||||
2013 S-1 July Registered Offering | |||||
On July 19, 2013, to obtain funding for working capital purposes, the Company entered into subscription agreements with certain investors (the “Investors”) relating to the sale by the Company of (i) 20,000,000 Units (each a “Unit”, and collectively, the “Units”), with each Unit consisting of (x) one share of common stock, par value $0.001 per share, and (y) one Series A Warrant to purchase one share of the Company’s common stock at an exercise price of $0.15 per share and (ii) 20,000,000 Series B Warrants, each to purchase one Unit, for aggregate gross proceeds of $3,000,000, before placement agent fees and other estimated offering expenses and fees (the “Offering”). The Units were not issued or certificated. The Investors received only shares of common stock, Series A Warrants and Series B Warrants. The common stock, the Series A Warrants and the Series B Warrants were and may be transferred separately immediately after their issuance. Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, purchased 5,998,999 Units and 5,998,999 Series B Warrants in the Offering; and Ruslan Semechkin, the Company’s Chief Scientific Officer, purchased 667,667 Units and 667,667 Series B Warrants in the Offering for an aggregate price of $1,000,000. | |||||
On July 19, 2013, the Company also entered into a placement agent agreement (the “Placement Agent Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act on a reasonable best efforts basis for the Offering. The Company paid the Placement Agent a cash fee equal to 5% of the gross proceeds from the Offering and reimbursed the Placement Agent for its reasonable out-of-pocket expenses of $75,000. The Company also issued 666,666 Placement Agent Warrants to purchase Units equal to 5% of the aggregate number of Units issued in the Offering (other than the Units issued to Andrey Semechkin and Ruslan Semechkin). The Placement Agent Warrants have substantially the same terms as the Series B Warrants, except that the Placement Agent Warrants (i) have an exercise price of $0.15 per Unit, subject to adjustments similar to those applicable to the Series A Warrants, (ii) have a term of five years, (iii) provide for a cashless exercise, and (iv) otherwise comply with the requirements of the Financial Institutions Regulatory Authority, Inc. (FINRA). The Company also agreed to pay the Placement Agent a cash solicitation fee equal to 5% of the gross proceeds received by the Company upon the exercise of the Series B Warrants under certain circumstances. | |||||
The Series A Warrants were immediately exercisable at an exercise price of $0.15 per share and will expire on the fifth anniversary of the initial date of issuance. Upon full exercise of the Series B Warrants, the Company could issue additional Series A Warrants to purchase up to an aggregate of 20,000,000 shares of the Company’s common stock. All Series A Warrants have the same expiration date. See Note 9, Stock Options and Warrants, Warrants Issued with Common Stock for detailed discussion of the anti-dilution provisions of the Series A Warrants. | |||||
The Series B Warrants were immediately exercisable at an initial exercise price of $0.15, subject to adjustment and expired on October 24, 2013. | |||||
The net proceeds to the Company from the Offering, after deducting placement agent fees and cash offering expenses borne by the Company, and excluding any proceeds, from the exercise of the warrants issued in the offering, was approximately $2,377,000. The Offering closed on July 24, 2013. | |||||
During the year ended December 31, 2013, the Company received net proceeds of $2,356,000 upon the exercise of 16,754,822 of the Series B Warrants issued in July 2013 for 16,754,822 additional Units, but prior to expiration of the Series B Warrants on October 24, 2013. The total additional Units consisted of 16,754,822 shares of common stock and 16,754,822 Series A Warrants. Of the 16,754,822 Series B Warrants exercised during the year ended December 31, 2013, there were 12,304,822 subject to an adjusted exercise price of $0.1452 per Unit for net proceeds of approximately $1,722,000. The remaining 4,450,000 were exercised prior to the adjustment date at $0.15 per Unit for net proceeds of approximately $634,000. See Note 9, Stock Options and Warrants, Warrants Issued with Common Stock for detailed discussion of the price adjustment provisions of the Series B Warrants. | |||||
Of the Series B Warrants exercised, Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, exercised 2,754,821 Series B Warrants; and Ruslan Semechkin, the Company’s Chief Scientific Officer, exercised 667,667 Series B Warrants for an aggregate price of $497,000. | |||||
In addition, during the year ended December 31, 2013, the Company received net proceeds of $30,000 upon the exercise of 200,000 of the Series A Warrants issued in July 2013 for 200,000 shares of common stock at an exercise price of $0.15 per share. | |||||
On October 24, 2013, the remaining 3,245,178 Series B Warrants expired unexercised. At December 31, 2013 and March 31, 2014, total Series A and Placement Agent warrants outstanding were 36,554,822 and 666,666, respectively, which the Company has reserved 37,888,154 shares of common stock for future issuance. 2013 Lincoln Park Capital Fund, LLC Stock Purchase Agreement | |||||
On December 10, 2013, the Company entered into a stock Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase up to an aggregate of $10,250,000 of common stock (subject to certain limitations) from time to time through January 2017. Of the aggregate $10,250,000 of common stock that may be sold to Lincoln Park, on December 11, 2013, the Company sold 1,666,666 shares of common stock to Lincoln Park for an aggregate purchase price of $250,000 pursuant to the Purchase Agreement, which is referred to as the Initial Purchase. Upon execution of the Purchase Agreement, the Company paid to Lincoln Park $155,000, as a cash fee, for their commitment to purchase additional shares of common stock under the Purchase Agreement. | |||||
Also on December 10, 2013, the Company entered into a Registration Rights Agreement with Lincoln Park, pursuant to which the Company filed with the SEC an S-1 Registration Statement to register for resale under the Securities Act of 1933, as amended, or the Securities Act, the shares that have been or may be issued to Lincoln Park under the Purchase Agreement. The S-1 Registration Statement filed with the Securities and Exchange Commission in December 2013 and amended in January 2014 was declared effective on January 13, 2014. | |||||
During the three months ended March 31, 2014, the Company sold 5,200,000 shares to Lincoln Park raising approximately $1,104,000 for working capital purposes. From commencement through to March 31, 2014, the Company has sold a total of 6,866,666 shares of common stock to Lincoln Park for an aggregate of $1,354,000 under the Agreement. As of March 31, 2014, there remained 13,133,334 shares available for sale up to a total of $8,896,000 under the Purchase Agreement with Lincoln Park. Subsequent to March 31, 2014, from April 1, 2014 through to May 2, 2014, the Company sold an additional 2,200,000 shares to Lincoln Park for an aggregate of approximately $360,000. | |||||
The Company may, from time to time and in its sole discretion, direct Lincoln Park to purchase shares of common stock in amounts up to 200,000 shares on any single business day so long as at least one business day has passed since the most recent purchase, which amounts may be increased to up to 300,000 shares and up to 400,000 shares, provided the closing price of the common stock exceeds a certain threshold, with a maximum limit of up to $500,000 per purchase, plus an additional “accelerated amount” under certain circumstances. There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control the timing and amount of any sales of common stock to Lincoln Park. The purchase price of the shares that may be sold to Lincoln Park under the Purchase Agreement will be based on the market price of the common stock immediately preceding the time of sale as computed under the Purchase Agreement without any fixed discount; provided that in no event will such shares be sold to Lincoln Park when the closing sale price is less than $0.05 per share, subject to adjustment as provided in the Purchase Agreement. | |||||
The purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business days used to compute such price. The Company may at any time in its sole discretion terminate the Purchase Agreement without fee, penalty or cost upon one business day notice. Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement. | |||||
Aspire Common Stock Purchase Agreement | |||||
On December 9, 2010, Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”), which provided that, subject to certain conditions and limitations, Aspire Capital was committed to purchase up to an aggregate of $25,000,000 of common stock over the term of the Purchase Agreement. The Purchase Agreement expired in December 2013. | |||||
On any day on which the principal market for shares of the Company’s common stock is open for trading, over the three-year term of the Purchase Agreement, the Company had the right, in its sole discretion, to provide Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase the number of shares of common stock specified in the Purchase Notice. The number of shares the Company could designate in the Purchase Notice varied based on the closing price of the common stock on the date of the Purchase Notice. The purchase price per share for each Purchase Notice was the lower of (i) the lowest sale price for the common stock on the date of sale or (ii) the arithmetic average of the three lowest closing sale prices for the common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date of those securities. | |||||
During the three months ended March 31, 2013, the Company issued 1,200,000 shares of common stock to Aspire Capital, raising $264,000, which was used to fund its research and operational activities. | |||||
Reserved Shares | |||||
At March 31, 2014, the Company had shares of common stock reserved for future issuance as follows: | |||||
Options outstanding | 23,279,793 | ||||
Options available for future grant | 12,621,950 | ||||
Convertible preferred stock | 47,282,944 | ||||
Warrants | 45,650,654 | ||||
128,835,341 | |||||
Related_Party_Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2014 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions | ' |
7. Related Party Transactions | |
Other than with respect to the purchases of Series C Preferred, Series D Preferred, Series G Preferred, and common stock discussed above, the Company’s related party transactions were for a facility lease. | |
During the first quarter of 2011, the Company executed an operating lease for its corporate offices with S Real Estate Holdings LLC. S Real Estate Holdings LLC is owned by Dr. Ruslan Semechkin, the Company’s Chief Scientific Officer and a director and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The lease agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are at least as favorable to the Company as could be obtained for comparable facilities from an unaffiliated party. For the three months ended March 31, 2014 and 2013, the Company recorded $35,000 and $28,000, respectively, in rent expense that was related to the facility lease arrangement with related parties. |
Income_Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2014 | |
Income Tax Disclosure [Abstract] | ' |
Income Taxes | ' |
8. Income Taxes | |
The Company estimated Federal and state tax losses for the current year and recorded a full valuation allowance against all net deferred tax assets. As such, no income tax provision has been recorded for the current period. The Company may be subject to IRC Code Sections 382 and 383, which could limit the amount of the net operating loss and tax credit carryovers that can be used in future years. The Company has not completed a study to assess whether an ownership change has occurred, as defined by IRC Code Sections 382 and 383, or whether there have been ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. The Company estimates that if such a change did occur, the federal and state net operating loss carryforwards and research and development credit carryforwards that can be utilized in the future will be significantly limited. There can be no assurances that the Company will ever be able to realize the benefit of some or all of the federal and state loss carryforwards or the credit carryforwards, either due to ongoing operating losses or due to ownership changes, which limit the usefulness of the carryforwards. |
Stock_Options_and_Warrants
Stock Options and Warrants | 3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||
Text Block [Abstract] | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Options and Warrants | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
9. Stock Options and Warrants | |||||||||||||||||||||||||||||||||||||||||||||||||
Stock Options | |||||||||||||||||||||||||||||||||||||||||||||||||
The Company has adopted the 2006 Equity Participation Plan (the “2006 Plan”). The options granted under the 2006 Plan may be either qualified or non-qualified options. Up to 15,000,000 options may be granted to employees, directors and consultants under this Plan. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant. | |||||||||||||||||||||||||||||||||||||||||||||||||
In April 2010, the Company adopted the 2010 Equity Participation Plan (the “2010 Plan”). The options granted under the 2010 Plan may be either qualified or non-qualified options. Up to 18,000,000 options may be granted to employees, directors and consultants under the 2010 Plan. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant. | |||||||||||||||||||||||||||||||||||||||||||||||||
In November and December of 2009, the Company issued non-qualified stock options to purchase 10,257,593 shares of common stock outside the 2006 and 2010 option plans to certain employees and consultants. These options vest over 50 months and expire no later than 10 years from the date of grant. | |||||||||||||||||||||||||||||||||||||||||||||||||
Total stock-based compensation expense for the three months ended March 31, 2014 and 2013 was comprised of the following (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||||||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||||||||||||||||||||||||||||
Cost of sales | $ | 15 | $ | — | |||||||||||||||||||||||||||||||||||||||||||||
Research and development | 70 | 84 | |||||||||||||||||||||||||||||||||||||||||||||||
Selling and marketing | 11 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||
General and administrative | 251 | 316 | |||||||||||||||||||||||||||||||||||||||||||||||
$ | 347 | $ | 409 | ||||||||||||||||||||||||||||||||||||||||||||||
Unrecognized compensation expense related to stock options as of March 31, 2014 was $1.5 million, which is expected to be recognized over a weighted average period of approximately 1.4 years. | |||||||||||||||||||||||||||||||||||||||||||||||||
In accordance with applicable authoritative guidance, the Company is required to establish assumptions and estimates of the weighted-average fair value of stock options granted, as well as use a valuation model to calculate the fair value of stock-based awards. The Company uses the Black-Scholes option-pricing model to determine the fair-value of stock-based awards. All options are amortized over the requisite service periods. Stock-based compensation for stock options granted to non-employees has been determined using the Black-Scholes option pricing model. These options are revalued at each reporting period until fully vested, with any change in fair value recognized in the consolidated statements of operations. | |||||||||||||||||||||||||||||||||||||||||||||||||
Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued: | |||||||||||||||||||||||||||||||||||||||||||||||||
Number of | Weighted | Weighted | Aggregate | ||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued | Average Exercise | Average | Intrinsic | ||||||||||||||||||||||||||||||||||||||||||||||
Under | Price Per | Remaining | Value | ||||||||||||||||||||||||||||||||||||||||||||||
2006 Plan and | Share | Contractual | (in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||
2010 Plan | Term | ||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 15,122,900 | $ | 1.18 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | 1,491,500 | $ | 0.26 | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | (586,000 | ) | $ | 0.61 | |||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2013 | 16,028,400 | $ | 1.12 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | (357,900 | ) | $ | 0.76 | |||||||||||||||||||||||||||||||||||||||||||||
Outstanding at March 31, 2014 | 15,670,500 | $ | 1.13 | 6.2 years | $ | 1 | |||||||||||||||||||||||||||||||||||||||||||
Vested and expected to vest at March 31, 2014 | 15,387,508 | $ | 1.14 | 6.1 years | $ | 1 | |||||||||||||||||||||||||||||||||||||||||||
Exercisable at March 31, 2014 | 11,821,845 | $ | 1.21 | 5.6 years | $ | — | |||||||||||||||||||||||||||||||||||||||||||
Number of | Weighted | Weighted | Aggregate | ||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued | Average Exercise | Average | Intrinsic | ||||||||||||||||||||||||||||||||||||||||||||||
Outside | Price Per | Remaining | Value | ||||||||||||||||||||||||||||||||||||||||||||||
the Plan | Share | Contractual | (in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||
Term | |||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 8,254,232 | $ | 0.65 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | (644,939 | ) | $ | 1 | |||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2013 | 7,609,293 | $ | 0.62 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Outstanding, vested and exercisable at March 31, 2014 | 7,609,293 | $ | 0.62 | 5.6 years | $ | — | |||||||||||||||||||||||||||||||||||||||||||
Restricted Stock Awards | |||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards are grants that entitle the holder to acquire shares of common stock at zero or a fixed price, which is typically nominal. The Company accounts for the restricted stock awards as issued and outstanding common stock, even though the shares covered by a restricted stock award cannot be sold, pledged, or otherwise disposed of until the award vests and any unvested shares may be reacquired by the Company for the original purchase price following the awardee’s termination of service. Annual grants of restricted stock awards are made to the outside board of directors on the date of the annual meeting of stockholders and typically vest in full at the next annual meeting of stockholders following the grant date. Beginning in 2013, additional annual grants of restricted stock awards were made to the non-employee members of the board of directors as partial compensation for their services. These awards vest quarterly at the end of each quarter. In addition, the Company has made restricted stock awards to non-employee consultants for their services, which generally vest in one year or less. | |||||||||||||||||||||||||||||||||||||||||||||||||
The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued: | |||||||||||||||||||||||||||||||||||||||||||||||||
Restricted | Weighted | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued | Average Grant Date | ||||||||||||||||||||||||||||||||||||||||||||||||
from the | Fair Value | ||||||||||||||||||||||||||||||||||||||||||||||||
2006 Plan and | |||||||||||||||||||||||||||||||||||||||||||||||||
2010 Plan | |||||||||||||||||||||||||||||||||||||||||||||||||
Unvested at December 31, 2012 | 335,000 | $ | 0.32 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | 961,000 | $ | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||
Vested | (1,029,750 | ) | $ | 0.27 | |||||||||||||||||||||||||||||||||||||||||||||
Forfeited | (121,250 | ) | $ | 0.25 | |||||||||||||||||||||||||||||||||||||||||||||
Unvested at December 31, 2013 | 145,000 | $ | 0.23 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | 529,500 | $ | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||
Vested | (121,875 | ) | $ | 0.24 | |||||||||||||||||||||||||||||||||||||||||||||
Forfeited | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Unvested at March 31, 2014 | 552,625 | $ | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||
The fair value of the restricted stock awards is based on the market value of the common stock on the date of grant. The total grant-date fair value of restricted stock awards vested during the three months ended March 31, 2014 and 2013 was approximately $29,000 and $41,000, respectively. The Company recognized approximately $39,000 and $68,000 of stock-based compensation expense related to the restricted stock awards for the three months ended March 31, 2014 and 2013, respectively. As of March 31, 2014, total unrecognized compensation costs related to unvested awards was approximately $102,000, which is expected to be recognized over a weighted-average period of approximately 0.75 years. | |||||||||||||||||||||||||||||||||||||||||||||||||
Warrants | |||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued with Preferred Stock | |||||||||||||||||||||||||||||||||||||||||||||||||
During 2008, in connection with the Company’s fund raising efforts, two warrants to purchase shares of common stock were issued with the purchase of one share of Series A Preferred Stock, where an additional 2,000,000 common stock warrants were outstanding and two warrants to purchase shares of common stock were issued with the purchase of one share of Series B Preferred Stock, where an additional 1,100,000 common stock warrants were outstanding. During the second quarter of 2010, the holders of the warrants issued to the purchasers of the Series A Preferred Stock and Series B Preferred Stock signed a waiver to give up their rights to the anti-dilution provisions related to the warrants and the exercise price was fixed at $0.25. | |||||||||||||||||||||||||||||||||||||||||||||||||
As of December 31, 2013, there were no outstanding warrants related to the Series A Preferred Stock and Series B Preferred Stock. Warrants related to the Series A Preferred Stock expired in January 2013, and warrants related to the Series B Preferred Stock expired in July 2013. | |||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued with Common Stock | |||||||||||||||||||||||||||||||||||||||||||||||||
2013 Securities Purchase Agreements for Common Stock | |||||||||||||||||||||||||||||||||||||||||||||||||
In conjunction with the Company’s sale of 10,125,000 shares of common stock on January 22, 2013, the Company issued warrants convertible into 5,062,500 shares of common stock at an exercise price of $0.20 per share. The warrants have a five-year term. These warrants are held by Dr. Andrey Semechkin and Dr. Simon Craw, the Company’s Co-Chairman and Chief Executive Officer and the Company’s Executive Vice President Business Development, respectively. | |||||||||||||||||||||||||||||||||||||||||||||||||
On March 12, 2013 the Company issued warrants convertible into 2,500,000 shares of common stock in conjunction with the sale of 5,000,000 shares of common stock. These warrants have a five-year term and an exercise price of $0.20 per share. Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer is the holder of 250,000 of these warrants. | |||||||||||||||||||||||||||||||||||||||||||||||||
2013 S-1 July Registered Offering | |||||||||||||||||||||||||||||||||||||||||||||||||
On July 24, 2013 the Company sold 20,000,000 Units, with each Unit consisting of one share of common stock and one Series A Warrant. The Series A Warrants are convertible into 20,000,000 shares of common stock at an exercise price of $0.15 per share. The warrants have a five year term and were immediately exercisable. In addition, the Company issued 20,000,000 Series B Warrants each to purchase one Unit. The Series B Warrants were immediately exercisable at an initial exercise price of $0.15 per Unit, subject to adjustment and expired on October 24, 2013. The Units issuable upon exercise of the Series B Warrants consisted of 20,000,000 shares of common stock and 20,000,000 Series A Warrants, which are convertible into an additional 20,000,000 shares of common stock at an exercise price of $0.15 per share. All Series A Warrants expire on the fifth anniversary of the transaction close, July 24, 2018, regardless of the date the Series A Warrants were issued. | |||||||||||||||||||||||||||||||||||||||||||||||||
On July 19, 2013, the Company also entered into a placement agent agreement (the “Placement Agent Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act on a reasonable best efforts basis for the Offering. The Company paid the Placement Agent a cash fee equal to 5% of the gross proceeds from the Offering and reimbursed the Placement Agent for its reasonable out-of-pocket expenses of $75,000. The Company also issued 666,666 Placement Agent Warrants to purchase Units equal to 5% of the aggregate number of Units issued in the Offering (other than the Units issued to Andrey Semechkin and Ruslan Semechkin). The Placement Agent Warrants have substantially the same terms as the Series B Warrants, except that the Placement Agent Warrants (i) have an exercise price of $0.15 per Unit, subject to adjustments similar to those applicable to the Series A Warrants, (ii) have a term of five years, (iii) provide for a cashless exercise, and (iv) otherwise comply with the requirements of the Financial Institutions Regulatory Authority, Inc. (FINRA). The Company also agreed to pay the Placement Agent a cash solicitation fee equal to 5% of the gross proceeds received by the Company upon the exercise of the Series B Warrants under certain circumstances. | |||||||||||||||||||||||||||||||||||||||||||||||||
The Series B Warrants were immediately exercisable at an initial exercise price of $0.15, subject to adjustment. Beginning at the close of trading on the 60th trading day following the date of issuance, and effective beginning on the fifth trading day immediately preceding such 60th trading day, the Series B Warrants were exercisable at a per unit exercise price equal to the lower of (i) the then-effective exercise price per unit and (ii) 80% of the closing bid price of the Company’s common stock on such 60th trading day. If prior to the close of trading on the 60th trading day after the date of issuance (and on any of the five trading days immediately preceding such day), a holder of the Series B Warrants had delivered one or more exercise notices to the Company and paid all or any part of the exercise price with respect thereto, then on the first trading day immediately following such 60th trading day the Company was obligated to deliver to such holder an amount in cash equal to the positive difference (if any) between (x) the exercise price actually paid by such holder and (y) the product of (I) the aggregate number of units elected to be purchased in such exercise notices, multiplied by (II) 80% of the closing bid price of the Company’s common stock on such 60th trading day. The Series B Warrants expired at the close of business on the 65th trading day following the date of issuance, October 24, 2013. The Series B Warrants were issued separately from the common stock and the Series A Warrants included in the Units, and were transferable separately, immediately thereafter. Series B Warrants were issued in certificated form only. Investors in the Offering received one Series B Warrant for each Unit purchased by them in the Offering. No additional consideration was paid by holders of the Series B Warrants. | |||||||||||||||||||||||||||||||||||||||||||||||||
The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction, as described in the Series A Warrants. The Series A Warrants also contain full ratchet anti-dilution protection upon the issuance of any common stock, securities convertible into common stock, or certain other issuances at a price below the then existing exercise price of the Series A Warrants, with certain exceptions. The exercise price and number of Units issuable on exercise of the Series B Warrants were subject to adjustment in the event of any stock split, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction, as described in the Series B Warrants. | |||||||||||||||||||||||||||||||||||||||||||||||||
The Series A Warrants are exercisable on a “cashless” basis in certain circumstances. In addition, in the event of a fundamental transaction that is (i) an all cash or substantially all cash transaction, (ii) a “Rule 13e 3 transaction” as defined in Rule 13e-3 under the Securities Exchange Act of 1934, as amended, or (iii) with certain limited exceptions, a fundamental transaction involving a person or entity not traded on The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market, then the Company or any successor entity will pay at the holder’s option, exercisable at any time concurrently with or within 45 days after the consummation of the fundamental transaction, an amount of cash equal to the value of the Series A Warrant as determined in accordance with the Black Scholes option pricing model. | |||||||||||||||||||||||||||||||||||||||||||||||||
The Company accounts for the warrants in accordance with current accounting guidance, which defines how freestanding contracts that are indexed to and potentially settled in a Company’s own stock should be measured and classified. The authoritative accounting guidance prescribes that only warrants issued under contracts that cannot be net-cash settled and are both indexed to and settled in the Company’s common stock can be classified as equity. As the Series A Warrant, Series B Warrant, and Placement Agent Warrant agreements did not meet the specific conditions for equity classification, the Company is required to classify the fair value of the warrants issued as a liability, with subsequent changes in fair value to be recorded as income (loss) in the statement of operations upon revaluation of the fair value of warrant liability at each reporting period. Valuation of the Warrants was estimated at March 31, 2014 and December 31, 2013 using the Monte-Carlo simulation model. The fair value is affected by changes in inputs to the model. The following assumptions were used as inputs to the model at March 31, 2014: stock price of $0.19 and warrant exercise price of $0.15 as of the valuation date; the Company’s historical stock price volatility of 83.9%; risk free interest rate on U.S. treasury notes of 1.45%; warrant expiration of 4.32 years; and a zero dividend rate for the Series A Warrants and the Placement Agent Warrants; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $0.15 per share. The following assumptions were used as inputs to the model at December 31, 2013: stock price of $0.21 and warrant exercise price of $0.15 as of the valuation date; the Company’s historical stock price volatility of 84.3%; risk free interest rate on U.S. treasury notes of 1.55%; warrant expiration of 4.56 years; and a zero dividend rate for the Series A Warrants and the Placement Agent Warrants; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $0.15 per share. | |||||||||||||||||||||||||||||||||||||||||||||||||
The fair value of the warrant liability at the issuance date exceeded the gross proceeds received for the common shares, Series A Warrants and the Series B Warrants by $1,390,000. The Series A Warrants, Series B Warrants, and Placement Agent Warrants had fair values of $1,725,000, $2,645,000 and $115,000 at issuance, respectively. The classification and valuation of the warrants resulted in total warrant liabilities of $4,485,000, $4,925,000, and $4,302,000 as of the issuance date of July 24, 2013 and the revaluation dates of December 31, 2013 and March 31, 2014, respectively. During the three months ended March 31, 2014, the Company recorded a net change in fair value of warrant liability gain of $623,000, in the unaudited condensed consolidated statements of operations related to the change in fair value due to the revaluation at March 31, 2014. | |||||||||||||||||||||||||||||||||||||||||||||||||
Series A and B Warrant Exercises—There were no warrant exercises during the three months ended March 31, 2014. During the year ended December 31, 2013, the Company received net proceeds of $2,356,000 upon the exercise of 16,754,822 of the Series B Warrants issued in July 2013 for 16,754,822 additional Units, but prior to the expiration of the Series B Warrants on October 24, 3013. The total additional Units consisted of 16,754,822 shares of common stock and 16,754,822 Series A Warrants. Of the Series B Warrants exercised, Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, exercised 2,754,821 Series B Warrants; and Ruslan Semechkin, the Company’s Chief Scientific Officer, exercised 667,667 Series B Warrants for an aggregate price of $497,000. | |||||||||||||||||||||||||||||||||||||||||||||||||
In addition, during the year ended December 31, 2013, the Company received net proceeds of $30,000 upon the exercise of 200,000 of the Series A Warrants issued in July 2013 for 200,000 shares of common stock at an exercise price of $0.15 per share. | |||||||||||||||||||||||||||||||||||||||||||||||||
Series B Price Adjustment—The Series B Warrants were subject to an exercise price adjustment on the 60th trading day following issuance in July 2013. On October 17, 2013, the adjustment date, the adjusted exercise price was calculated at a 20% discount to the closing bid price on the adjustment date. The closing bid price on the adjustment date was $0.1815 per share, which resulted in an adjusted exercise price of $0.1452 per Unit. This adjusted exercise price was retroactively applied to all exercises from the period of October 10th through to the expiration date of October 24th. Of the 16,754,822 Series B Warrants exercised during the year ended December 31, 2013, there were 12,304,822 subject to the adjusted exercise price of $0.1452 per Unit for net proceeds of approximately $1,722,000. The remaining 4,450,000 were exercised prior to the adjustment date at $0.15 per Unit for net proceeds of approximately $634,000. | |||||||||||||||||||||||||||||||||||||||||||||||||
Expiration of Series B Warrants—On October 24, 2013, the remaining 3,245,178 Series B Warrants expired unexercised. As of March 31, 2014 and December 31, 2013, there were 36,554,822 Series A Warrants and 666,666 Placement Agent Warrants outstanding which the Company has reserved 37,888,154 shares of common stock for future issuance. | |||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Issued with Other Financings | |||||||||||||||||||||||||||||||||||||||||||||||||
During 2007 and 2008, the Company entered into various agreements to borrow working capital and as part of these agreements, the Company issued warrants to the holders to purchase common stock. The Company issued 1,400,000 warrants to YKA Partners, an affiliated company of its former Co-Chairman of the Board with an exercise price of $0.25 per share, all of which expired unexercised in August 2013. | |||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Issued in Connection with SkinCare Marketing Agreement | |||||||||||||||||||||||||||||||||||||||||||||||||
In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, with a third party marketing organization. According to the terms of the agreement as described in Note 10 below, Commitments and Contingencies, under Marketing Arrangement and Agreement, the third party marketing organization would provide assistance to LSC to sell its skin care products through various specific proprietary mailings. The agreement provides for two tranches of common stock warrants issued by the Company for the benefit of the third party marketing organization for 100,000 shares each, with strike prices of $1.50 and $2.00, respectively, vesting over four quarters, and a warrant term of five years. As of March 31, 2014 and December 31, 2013, there were 200,000 warrants outstanding. These warrants expire in September 2016. | |||||||||||||||||||||||||||||||||||||||||||||||||
Share data related to warrant transactions through March 31, 2014 were as follows: | |||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock | Common Stock | Units | Common Stock | Price per Warrant | |||||||||||||||||||||||||||||||||||||||||||||
Series A | Series B | Series A | Series B | Placement | YKA | Skin Care | Jan 2013 | Mar-13 | Total | Range | Weighted | ||||||||||||||||||||||||||||||||||||||
Agent | Loan | Marketing | Financing | Financing | Warrants | Average | |||||||||||||||||||||||||||||||||||||||||||
Exercise Price | |||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding, December 31, 2012 | 1,600,000 | 300,000 | — | — | — | 1,400,000 | 200,000 | — | — | 3,500,000 | $ | 0.25-2.00 | $ | 0.336 | |||||||||||||||||||||||||||||||||||
2013 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued | 36,754,822 | 20,000,000 | 666,666 | 5,062,500 | 2,500,000 | 64,983,988 | $ | 0.15-0.20 | $ | 0.156 | |||||||||||||||||||||||||||||||||||||||
Exercised | (200,000 | ) | (16,754,822 | ) | (16,954,822 | ) | $ | 0.145-0.15 | $ | 0.147 | |||||||||||||||||||||||||||||||||||||||
Forfeited/Cancelled | (1,600,000 | ) | (300,000 | ) | (3,245,178 | ) | (1,400,000 | ) | (6,545,178 | ) | $ | 0.15-0.25 | $ | 0.198 | |||||||||||||||||||||||||||||||||||
Outstanding, December 31, 2013 | — | — | 36,554,822 | — | 666,666 | — | 200,000 | 5,062,500 | 2,500,000 | 44,983,988 | $ | 0.145-2.00 | $ | 0.166 | |||||||||||||||||||||||||||||||||||
2013 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Forfeited/Cancelled | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding, March 31, 2014 | — | — | 36,554,822 | — | 666,666 | — | 200,000 | 5,062,500 | 2,500,000 | 44,983,988 | $ | 0.145-2.00 | $ | 0.166 | |||||||||||||||||||||||||||||||||||
Commitments_and_Contingencies
Commitments and Contingencies | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||
Commitments and Contingencies | ' | ||||
10. Commitments and Contingencies | |||||
Leases | |||||
The Company has established its primary research facility in 8,215 square feet of leased office and laboratory space in Oceanside, California. The lease for this facility expires in August 2016. The current base rent is $8,588 per month. The facility has leasehold improvements which include cGMP (current Good Manufacturing Practices) level clean rooms designed for the derivation of clinical-grade stem cells and their differentiated derivatives, research laboratories for the Company’s stem cell differentiation studies and segregated rooms for biohazard control and containment of human donor tissue. The monthly base rent will increase by 3% annually on the anniversary date of the agreement. | |||||
The Company leases a 5,520 square foot manufacturing facility in Frederick, Maryland, which is used for laboratory and administrative purposes. The current base rent is $11,644. The initial term of the lease expires in December 2015 and there is an option for an additional five years. The laboratory is being used to develop and manufacture the Company’s research products and the administration facility is used for sales and marketing and general administrative purposes. The manufacturing laboratory space has clean rooms and is fitted with the necessary water purification, refrigeration, labeling equipment and standard manufacturing equipment to manufacture, package, store, and distribute media products. | |||||
On February 25, 2011, the Company entered into a lease agreement (the “Lease Agreement”) with S Real Estate Holdings LLC to allow the Company to expand into new corporate offices located at 5950 Priestly Drive, Carlsbad, California. The building is used for administrative purposes, but could also be used for research and development purposes if such space is needed in the future. The lease initially covered approximately 4,653 square feet, starting on March 1, 2011, and was amended to cover approximately 8,199 square feet effective July 1, 2011, and to cover approximately 9,848 square feet effective January 1, 2013. The lease expires on February 29, 2016, subject to the Company’s right to extend the term for up to five additional years. The Company began paying rent at an initial rate of $5,118 per month and the rate was amended effective July 1, 2011 and January 1, 2013 to account for additional square footage occupied by the Company. The current base rent is $11,837 per month. The monthly base rent will increase by 3% annually on the anniversary date of the agreement. The Company is also obligated to pay a portion of the utilities for the building and increases in property tax and insurance. | |||||
S Real Estate Holdings LLC is owned by Dr. Ruslan Semechkin, the Company’s Chief Scientific Officer and a director, and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The Lease Agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are consistent with the terms that could be obtained for comparable facilities from an unaffiliated party. | |||||
The Company incurred rent expense of $79,000 and $74,000 for the three months ended March 31, 2014 and 2013, respectively. | |||||
Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2014, are as follows (in thousands): | |||||
Amount | |||||
2014 (remaining nine months) | $ | 291 | |||
2015 | 397 | ||||
2016 | 101 | ||||
2017 | 3 | ||||
Total | $ | 792 | |||
Marketing Arrangement and Agreement | |||||
In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, superseding the terms of a previous arrangement with a third party marketing organization. According to the agreement, the third party marketing organization will continue to provide assistance to Lifeline Skin Care, Inc., (“LSC”) a wholly-owned subsidiary of International Stem Cell, to sell skin care products through various specific proprietary mailings. In exchange for such services, the Company will pay 20% of net revenues for Direct Sales (as defined in the agreement) generated from the proprietary mailings. In addition, the Company agreed to pay 10% of net revenues for Referral Sales. The agreement specifies that the parties do not intend to create a joint venture, and that either party may terminate the agreement upon 30-day written notice. In addition, the agreement provided for two tranches of common stock warrants issued by the Company for the benefit of the third party marketing organization for 100,000 shares each, with strike prices of $1.50 and $2.00, respectively, with vesting over four quarters, and warrant term of five years. Subsequently in July 2012, the Company renegotiated the commission structure to reflect slightly lower rates, 18% on net revenues derived from direct sales and 9% on net revenues derived from referral sales. LSC incurred $13,000 and $24,000 as commission expenses during the three months ended March 31, 2014 and 2013, respectively, under the terms of this arrangement and agreement. | |||||
Customer Concentration | |||||
During the three months ended March 31, 2014 for the Biomedical market segment, one customer accounted for 20% of consolidated revenues. During the three months ended March 31, 2013 for the Biomedical market segment, one customer, accounted for 16% of our consolidated revenues. No other single customer accounted for more than 10% of revenues for any period presented. |
Segments_and_Geographic_Inform
Segments and Geographic Information | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Segment Reporting [Abstract] | ' | ||||||||
Segments and Geographic Information | ' | ||||||||
11. Segments and Geographic Information | |||||||||
The Company’s chief operating decision-maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information by each reportable company’s statement of operations. The Company operates the business on the basis of three reporting segments, the parent company and two wholly-owned subsidiaries: | |||||||||
International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of hpSCs for the treatment of various diseases such as Parkinson’s disease, liver diseases and corneal blindness; | |||||||||
Lifeline Skin Care, Inc. for the Cosmeceutical Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells; | |||||||||
Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products including over 130 human cell culture products, including frozen human “primary” cells and the reagents (called “media”) needed to grow, maintain and differentiate the cells. | |||||||||
Revenues, Expenses and Operating Income (loss) | |||||||||
The Company does not measure the performance of its segments on any asset-based metrics. Therefore, segment information is presented only for operating income (loss). Revenues, expenses and operating income (loss) by market segment were as follows (in thousands): | |||||||||
For the Three Months | |||||||||
Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Revenues: | |||||||||
Cosmeceutical market | $ | 803 | $ | 650 | |||||
Biomedical market | 846 | 635 | |||||||
Total revenues | 1,649 | 1,285 | |||||||
Operating expenses: | |||||||||
Therapeutic market | 2,220 | 1,841 | |||||||
Cosmeceutical market | 788 | 603 | |||||||
Biomedical market | 706 | 554 | |||||||
Total operating expenses | 3,714 | 2,998 | |||||||
Operating income (loss): | |||||||||
Therapeutic market | (2,220 | ) | (1,841 | ) | |||||
Cosmeceutical market | 15 | 47 | |||||||
Biomedical market | 140 | 81 | |||||||
Total operating income (loss) | $ | (2,065 | ) | $ | (1,713 | ) | |||
Geographic Information | |||||||||
The Company’s wholly-owned subsidiaries are located in Maryland and California, and have customer and vendor relationships worldwide. Significant revenues in the following regions are those that are attributable to the individual countries within the region to which the product was shipped (in thousands): | |||||||||
For the Three Months Ended | |||||||||
March 31, | |||||||||
2014 | 2013 | ||||||||
North America | $ | 1,349 | $ | 1,018 | |||||
Asia | 178 | 127 | |||||||
Europe | 109 | 111 | |||||||
All other regions | 13 | 29 | |||||||
Total | $ | 1,649 | $ | 1,285 | |||||
Subsequent_Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2014 | |
Subsequent Events [Abstract] | ' |
Subsequent Events | ' |
12. Subsequent Events | |
Additional Financing from Lincoln Park Capital Fund, LLC | |
Under the Purchase Agreement the Company entered into with Lincoln Park in December 2013, it may sell up to an aggregate of $10,250,000 of common stock to Lincoln Park from time to time through January 2017. Subsequent to March 31, 2014, from April 1, 2014 through to May 2, 2014, the Company sold an additional 2,200,000 shares to Lincoln Park for an aggregate of approximately $360,000. |
Organization_and_Significant_A1
Organization and Significant Accounting Policies (Policies) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Business Combination and Corporate Restructure | ' | ||||||||||||||||
Business Combination and Corporate Restructure | |||||||||||||||||
BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now the wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation. | |||||||||||||||||
Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval. | |||||||||||||||||
On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 20,000,000 shares of ISC California Common Stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California. | |||||||||||||||||
Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmeceutical products, utilizing an extract derived from the Company’s human parthenogenetic stem cell technologies. | |||||||||||||||||
Going Concern | ' | ||||||||||||||||
Going Concern | |||||||||||||||||
The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $677,000 per month, excluding capital expenditures and patent costs averaging $52,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow, and that such cash flows will be sufficient to sustain the Company’s operations through 2014. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company is a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. | |||||||||||||||||
Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. In December 2013, the Company filed a registration statement with the SEC, which allows the Company to sell up to $10,250,000 of common stock to Lincoln Park Capital Fund, LLC (“Lincoln Park”) from time to time through January 2017 at the Company’s discretion. The registration statement was declared effective on January 13, 2014. However, the Company cannot predict the timing or amount of any funds that it may actually receive. During the first quarter of 2014, to obtain funding for working capital purposes, the Company sold a total of 5,200,000 shares of common stock under the stock Purchase Agreement with Lincoln Park, raising approximately $1,104,000. For further discussion, see Note 6, Capital Stock. Subsequent to March 31, 2014 through to May 2, 2014, the Company has sold an additional 2,200,000 shares of common stock under this stock Purchase Agreement, for an aggregate of approximately $360,000, as discussed in Note 12, Subsequent Events. | |||||||||||||||||
Basis of Presentation | ' | ||||||||||||||||
Basis of Presentation | |||||||||||||||||
The Company is a biotechnology company focused on therapeutic and clinical product development with multiple long-term therapeutic opportunities and two revenue-generating subsidiaries with potential for increased future revenues. The Company was in the development stage from inception through the quarter ended September 30, 2013. During the quarter ended December 31, 2013, the Company exited the development stage based on a consistent, increasing revenue trend and more significant revenue generated from its two commercial businesses. The Company generated product revenues from the two commercial businesses of $6,147,000 for the year ended December 31, 2013. The Company currently has no revenue generated from its principal operations in therapeutic and clinical product development through research and development efforts. | |||||||||||||||||
The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. | |||||||||||||||||
These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2013. When used in these notes, the terms “Company,” “we,” “us,” or “our” mean International Stem Cell Corporation and all entities included in the unaudited condensed consolidated financial statements. | |||||||||||||||||
In the opinion of management, the unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2013 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year. | |||||||||||||||||
Principles of Consolidation | ' | ||||||||||||||||
Principles of Consolidation | |||||||||||||||||
The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated. | |||||||||||||||||
Reclassification | ' | ||||||||||||||||
Reclassification | |||||||||||||||||
Certain amounts within the unaudited condensed consolidated statements of operations for the prior period have been reclassified to conform to the current period presentation. These reclassifications had no impact on the Company’s previously reported results of operations. | |||||||||||||||||
Cash Equivalents | ' | ||||||||||||||||
Cash Equivalents | |||||||||||||||||
The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. | |||||||||||||||||
Restricted Cash | ' | ||||||||||||||||
Restricted Cash | |||||||||||||||||
The Company is required to maintain $50,000 in a restricted certificate of deposit account in order to fully collateralize two revolving credit card accounts. | |||||||||||||||||
Inventories | ' | ||||||||||||||||
Inventories | |||||||||||||||||
Inventories are accounted for using the first-in, first-out (FIFO) method for LSC products, and specific identification method for LCT products. Inventory balances are stated at the lower of cost or market. Laboratory supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly. | |||||||||||||||||
Accounts Receivable | ' | ||||||||||||||||
Accounts Receivable | |||||||||||||||||
Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of March 31, 2014 and December 31, 2013, the Company had an allowance for bad debt totaling $19,000. | |||||||||||||||||
Property and Equipment | ' | ||||||||||||||||
Property and Equipment | |||||||||||||||||
Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset. | |||||||||||||||||
Intangible Assets | ' | ||||||||||||||||
Intangible Assets | |||||||||||||||||
Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and patent licenses were recorded at cost of $2,867,000 and $2,760,000 at March 31, 2014 and December 31, 2013, respectively, and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license. Amortization expense for the three months ended March 31, 2014 and 2013 amounted to $15,000, and is included in research and development expense. Accumulated amortization as of March 31, 2014 and December 31, 2013 was $525,000 and $510,000, respectively. Additional information regarding patents and patent licenses is included in Note 4. | |||||||||||||||||
Long-Lived Asset Impairment | ' | ||||||||||||||||
Long-Lived Asset Impairment | |||||||||||||||||
The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company did not recognize material impairments on its long-lived assets during the three months ended March 31, 2014 and 2013. | |||||||||||||||||
Product Sales | ' | ||||||||||||||||
Product Sales | |||||||||||||||||
The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has lapsed. LCT contributed 51% and 49% of total revenue during the three months ended March 31, 2014 and 2013, respectively. LSC contributed 49% and 51% of total revenue during the three months ended March 31, 2014 and 2013, respectively. | |||||||||||||||||
Deferred Revenue and Allowance for Sales Returns | ' | ||||||||||||||||
Deferred Revenue and Allowance for Sales Returns | |||||||||||||||||
The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee to be approximately 3% for the years ended December 31, 2013 and 2012. At March 31, 2014 and December 31, 2013, the estimated allowance for sales returns was $10,000. At March 31, 2014 and December 31, 2013, net deferred revenue totaled $0 and $3,000, respectively. | |||||||||||||||||
Cost of Sales | ' | ||||||||||||||||
Cost of Sales | |||||||||||||||||
Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future. | |||||||||||||||||
Research and Development Costs | ' | ||||||||||||||||
Research and Development Costs | |||||||||||||||||
Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses. | |||||||||||||||||
Stock-Based Compensation | ' | ||||||||||||||||
Stock-Based Compensation | |||||||||||||||||
The Company recognized stock-based compensation expense associated with stock options and other stock-based awards in accordance with the authoritative guidance for stock-based compensation. The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award, and is recognized as expense on a straight-line basis, net of estimated forfeitures over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The fair value of restricted stock awards is based on the market value of our common stock on the date of grant. | |||||||||||||||||
Fair Value Measurements | ' | ||||||||||||||||
Fair Value Measurements | |||||||||||||||||
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: | |||||||||||||||||
Level 1 | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; | ||||||||||||||||
Level 2 | Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and | ||||||||||||||||
Level 3 | Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). | ||||||||||||||||
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. | |||||||||||||||||
The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of March 31, 2014 (in thousands): | |||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||
ASSETS: | |||||||||||||||||
Cash equivalents | $ | 5 | $ | 5 | $ | — | $ | — | |||||||||
LIABILITIES: | |||||||||||||||||
Warrants to purchase common stock | $ | 4,302 | $ | — | $ | — | $ | 4,302 | |||||||||
The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2013 (in thousands): | |||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||
ASSETS: | |||||||||||||||||
Cash equivalents | $ | 5 | $ | 5 | $ | — | $ | — | |||||||||
LIABILITIES: | |||||||||||||||||
Warrants to purchase common stock | $ | 4,925 | $ | — | $ | — | $ | 4,925 | |||||||||
The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands): | |||||||||||||||||
Warrants to purchase | |||||||||||||||||
common stock | |||||||||||||||||
Beginning balance at December 31, 2012 | $ | — | |||||||||||||||
Issuances of warrants | 5,986 | ||||||||||||||||
Exercise of warrants | (1,815 | ) | |||||||||||||||
Adjustments to estimated fair value | 754 | ||||||||||||||||
Ending balance at December 31, 2013 | 4,925 | ||||||||||||||||
Issuances of warrants | — | ||||||||||||||||
Exercise of warrants | — | ||||||||||||||||
Adjustments to estimated fair value | (623 | ) | |||||||||||||||
Ending balance at March 31, 2014 | $ | 4,302 | |||||||||||||||
Income Taxes | ' | ||||||||||||||||
Income Taxes | |||||||||||||||||
The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. | |||||||||||||||||
Use of Estimates | ' | ||||||||||||||||
Use of Estimates | |||||||||||||||||
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates. | |||||||||||||||||
Fair Value of Financial Instruments | ' | ||||||||||||||||
Fair Value of Financial Instruments | |||||||||||||||||
The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of March 31, 2014 and December 31, 2013 approximate their fair values because of the short-term nature of those instruments. The fair value of certain warrants is determined at each quarterly reporting date as necessary using the Monte-Carlo valuation methodology. | |||||||||||||||||
Income (Loss) Per Common Share | ' | ||||||||||||||||
Income (Loss) Per Common Share | |||||||||||||||||
The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At March 31, 2014, there were 552,625 non-vested restricted stock awards, 19,431,138 vested and 3,848,655 non-vested stock options outstanding, and 44,983,988 warrants outstanding, which were convertible into 45,650,654 shares of common stock; and at March 31, 2013, there were 822,500 non-vested restricted stock awards, 15,864,448 vested and 6,811,745 non-vested stock options outstanding, and 9,462,500 warrants outstanding, which were convertible into 9,462,500 shares of common stock. These restricted stock awards, stock options and warrants were not included in the diluted loss per share calculation because the effect would have been anti-dilutive. | |||||||||||||||||
Comprehensive Income | ' | ||||||||||||||||
Comprehensive Income | |||||||||||||||||
Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net loss from operations for the three months ended March 31, 2014 and 2013. | |||||||||||||||||
Registration Payment Arrangements | ' | ||||||||||||||||
Registration Payment Arrangements | |||||||||||||||||
In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities. | |||||||||||||||||
Recent Accounting Pronouncements | ' | ||||||||||||||||
Recent Accounting Pronouncements | |||||||||||||||||
In July 2013, the FASB issued an accounting standards update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company has adopted this guidance at the beginning of the first quarter of fiscal year 2014. The adoption of this standard does not have a material impact on the Company’s financial position, results of operations or related financial statement disclosures. |
Organization_and_Significant_A2
Organization and Significant Accounting Policies (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Fair Values of Assets and Liabilities | ' | ||||||||||||||||
The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of March 31, 2014 (in thousands): | |||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||
ASSETS: | |||||||||||||||||
Cash equivalents | $ | 5 | $ | 5 | $ | — | $ | — | |||||||||
LIABILITIES: | |||||||||||||||||
Warrants to purchase common stock | $ | 4,302 | $ | — | $ | — | $ | 4,302 | |||||||||
The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2013 (in thousands): | |||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||
ASSETS: | |||||||||||||||||
Cash equivalents | $ | 5 | $ | 5 | $ | — | $ | — | |||||||||
LIABILITIES: | |||||||||||||||||
Warrants to purchase common stock | $ | 4,925 | $ | — | $ | — | $ | 4,925 | |||||||||
Fair Value Measurement and Unobservable Rollforward Activity of Liabilities | ' | ||||||||||||||||
The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands): | |||||||||||||||||
Warrants to purchase | |||||||||||||||||
common stock | |||||||||||||||||
Beginning balance at December 31, 2012 | $ | — | |||||||||||||||
Issuances of warrants | 5,986 | ||||||||||||||||
Exercise of warrants | (1,815 | ) | |||||||||||||||
Adjustments to estimated fair value | 754 | ||||||||||||||||
Ending balance at December 31, 2013 | 4,925 | ||||||||||||||||
Issuances of warrants | — | ||||||||||||||||
Exercise of warrants | — | ||||||||||||||||
Adjustments to estimated fair value | (623 | ) | |||||||||||||||
Ending balance at March 31, 2014 | $ | 4,302 | |||||||||||||||
Inventory_Tables
Inventory (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Summary of the Components of Inventories | ' | ||||||||
The components of inventories are as follows (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 178 | $ | 147 | |||||
Work in process | 397 | 446 | |||||||
Finished goods | 912 | 902 | |||||||
Total | 1,487 | 1,495 | |||||||
Less: allowance for inventory obsolescence | (130 | ) | (126 | ) | |||||
Inventory, net | $ | 1,357 | $ | 1,369 | |||||
Property_and_Equipment_Tables
Property and Equipment (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Property Plant And Equipment [Abstract] | ' | ||||||||
Summary of Property and Equipment | ' | ||||||||
Property and equipment consists of the following (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
Machinery and equipment | $ | 1,178 | $ | 1,170 | |||||
Computer equipment | 249 | 246 | |||||||
Office equipment | 205 | 203 | |||||||
Leasehold improvements | 745 | 745 | |||||||
2,377 | 2,364 | ||||||||
Less: accumulated depreciation and amortization | (1,635 | ) | (1,534 | ) | |||||
Property and equipment, net | $ | 742 | $ | 830 | |||||
Patent_Licenses_Tables
Patent Licenses (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Goodwill And Intangible Assets Disclosure [Abstract] | ' | ||||
Summary of Future Amortization Expense Related to Intangible Assets Subject to Amortization | ' | ||||
At March 31, 2014, future amortization expense related to intangible assets subject to amortization is expected to be as follows (in thousands): | |||||
Amount | |||||
2014 (remaining nine months) | $ | 48 | |||
2015 | 63 | ||||
2016 | 64 | ||||
2017 | 64 | ||||
2018 | 64 | ||||
Thereafter | 2,018 | ||||
Total | $ | 2,321 | |||
Advances_Tables
Advances (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Text Block [Abstract] | ' | ||||||||
Schedule of Advances from Nonaffiliated Collaboration | ' | ||||||||
As of March 31, 2014 no revenues were realized from this agreement. | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
BioTime, Inc. (in thousands) | $ | 250 | $ | 250 |
Capital_Stock_Tables
Capital Stock (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Equity [Abstract] | ' | ||||
Summary of Shares of Common Stock Reserved for Future Issuance | ' | ||||
At March 31, 2014, the Company had shares of common stock reserved for future issuance as follows: | |||||
Options outstanding | 23,279,793 | ||||
Options available for future grant | 12,621,950 | ||||
Convertible preferred stock | 47,282,944 | ||||
Warrants | 45,650,654 | ||||
128,835,341 | |||||
Stock_Options_and_Warrants_Tab
Stock Options and Warrants (Tables) | 3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||
Text Block [Abstract] | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Total Stock-Based Compensation Expense | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
Total stock-based compensation expense for the three months ended March 31, 2014 and 2013 was comprised of the following (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
March 31, | March 31, | ||||||||||||||||||||||||||||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||||||||||||||||||||||||||||
Cost of sales | $ | 15 | $ | — | |||||||||||||||||||||||||||||||||||||||||||||
Research and development | 70 | 84 | |||||||||||||||||||||||||||||||||||||||||||||||
Selling and marketing | 11 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||
General and administrative | 251 | 316 | |||||||||||||||||||||||||||||||||||||||||||||||
$ | 347 | $ | 409 | ||||||||||||||||||||||||||||||||||||||||||||||
Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued: | |||||||||||||||||||||||||||||||||||||||||||||||||
Number of | Weighted | Weighted | Aggregate | ||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued | Average Exercise | Average | Intrinsic | ||||||||||||||||||||||||||||||||||||||||||||||
Under | Price Per | Remaining | Value | ||||||||||||||||||||||||||||||||||||||||||||||
2006 Plan and | Share | Contractual | (in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||
2010 Plan | Term | ||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 15,122,900 | $ | 1.18 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | 1,491,500 | $ | 0.26 | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | (586,000 | ) | $ | 0.61 | |||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2013 | 16,028,400 | $ | 1.12 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | (357,900 | ) | $ | 0.76 | |||||||||||||||||||||||||||||||||||||||||||||
Outstanding at March 31, 2014 | 15,670,500 | $ | 1.13 | 6.2 years | $ | 1 | |||||||||||||||||||||||||||||||||||||||||||
Vested and expected to vest at March 31, 2014 | 15,387,508 | $ | 1.14 | 6.1 years | $ | 1 | |||||||||||||||||||||||||||||||||||||||||||
Exercisable at March 31, 2014 | 11,821,845 | $ | 1.21 | 5.6 years | $ | — | |||||||||||||||||||||||||||||||||||||||||||
Number of | Weighted | Weighted | Aggregate | ||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued | Average Exercise | Average | Intrinsic | ||||||||||||||||||||||||||||||||||||||||||||||
Outside | Price Per | Remaining | Value | ||||||||||||||||||||||||||||||||||||||||||||||
the Plan | Share | Contractual | (in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||
Term | |||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 8,254,232 | $ | 0.65 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | (644,939 | ) | $ | 1 | |||||||||||||||||||||||||||||||||||||||||||||
Outstanding at December 31, 2013 | 7,609,293 | $ | 0.62 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Canceled or expired | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Outstanding, vested and exercisable at March 31, 2014 | 7,609,293 | $ | 0.62 | 5.6 years | $ | — | |||||||||||||||||||||||||||||||||||||||||||
Summary of Changes in Restricted Stock Award Activity | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued: | |||||||||||||||||||||||||||||||||||||||||||||||||
Restricted | Weighted | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued | Average Grant Date | ||||||||||||||||||||||||||||||||||||||||||||||||
from the | Fair Value | ||||||||||||||||||||||||||||||||||||||||||||||||
2006 Plan and | |||||||||||||||||||||||||||||||||||||||||||||||||
2010 Plan | |||||||||||||||||||||||||||||||||||||||||||||||||
Unvested at December 31, 2012 | 335,000 | $ | 0.32 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | 961,000 | $ | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||
Vested | (1,029,750 | ) | $ | 0.27 | |||||||||||||||||||||||||||||||||||||||||||||
Forfeited | (121,250 | ) | $ | 0.25 | |||||||||||||||||||||||||||||||||||||||||||||
Unvested at December 31, 2013 | 145,000 | $ | 0.23 | ||||||||||||||||||||||||||||||||||||||||||||||
Granted | 529,500 | $ | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||
Vested | (121,875 | ) | $ | 0.24 | |||||||||||||||||||||||||||||||||||||||||||||
Forfeited | — | $ | — | ||||||||||||||||||||||||||||||||||||||||||||||
Unvested at March 31, 2014 | 552,625 | $ | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||
Summary of Outstanding Warrants Related to Warrant Transactions | ' | ||||||||||||||||||||||||||||||||||||||||||||||||
Share data related to warrant transactions through March 31, 2014 were as follows: | |||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock | Common Stock | Units | Common Stock | Price per Warrant | |||||||||||||||||||||||||||||||||||||||||||||
Series A | Series B | Series A | Series B | Placement | YKA | Skin Care | Jan 2013 | Mar-13 | Total | Range | Weighted | ||||||||||||||||||||||||||||||||||||||
Agent | Loan | Marketing | Financing | Financing | Warrants | Average | |||||||||||||||||||||||||||||||||||||||||||
Exercise Price | |||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding, December 31, 2012 | 1,600,000 | 300,000 | — | — | — | 1,400,000 | 200,000 | — | — | 3,500,000 | $ | 0.25-2.00 | $ | 0.336 | |||||||||||||||||||||||||||||||||||
2013 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued | 36,754,822 | 20,000,000 | 666,666 | 5,062,500 | 2,500,000 | 64,983,988 | $ | 0.15-0.20 | $ | 0.156 | |||||||||||||||||||||||||||||||||||||||
Exercised | (200,000 | ) | (16,754,822 | ) | (16,954,822 | ) | $ | 0.145-0.15 | $ | 0.147 | |||||||||||||||||||||||||||||||||||||||
Forfeited/Cancelled | (1,600,000 | ) | (300,000 | ) | (3,245,178 | ) | (1,400,000 | ) | (6,545,178 | ) | $ | 0.15-0.25 | $ | 0.198 | |||||||||||||||||||||||||||||||||||
Outstanding, December 31, 2013 | — | — | 36,554,822 | — | 666,666 | — | 200,000 | 5,062,500 | 2,500,000 | 44,983,988 | $ | 0.145-2.00 | $ | 0.166 | |||||||||||||||||||||||||||||||||||
2013 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Exercised | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Forfeited/Cancelled | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding, March 31, 2014 | — | — | 36,554,822 | — | 666,666 | — | 200,000 | 5,062,500 | 2,500,000 | 44,983,988 | $ | 0.145-2.00 | $ | 0.166 | |||||||||||||||||||||||||||||||||||
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||
Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year | ' | ||||
Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2014, are as follows (in thousands): | |||||
Amount | |||||
2014 (remaining nine months) | $ | 291 | |||
2015 | 397 | ||||
2016 | 101 | ||||
2017 | 3 | ||||
Total | $ | 792 | |||
Segments_and_Geographic_Inform1
Segments and Geographic Information (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Segment Reporting [Abstract] | ' | ||||||||
Revenues, Expenses and Operating Income (Loss) by Market Segment | ' | ||||||||
Revenues, expenses and operating income (loss) by market segment were as follows (in thousands): | |||||||||
For the Three Months | |||||||||
Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Revenues: | |||||||||
Cosmeceutical market | $ | 803 | $ | 650 | |||||
Biomedical market | 846 | 635 | |||||||
Total revenues | 1,649 | 1,285 | |||||||
Operating expenses: | |||||||||
Therapeutic market | 2,220 | 1,841 | |||||||
Cosmeceutical market | 788 | 603 | |||||||
Biomedical market | 706 | 554 | |||||||
Total operating expenses | 3,714 | 2,998 | |||||||
Operating income (loss): | |||||||||
Therapeutic market | (2,220 | ) | (1,841 | ) | |||||
Cosmeceutical market | 15 | 47 | |||||||
Biomedical market | 140 | 81 | |||||||
Total operating income (loss) | $ | (2,065 | ) | $ | (1,713 | ) | |||
Summary of Significant Revenues in Following Regions | ' | ||||||||
Significant revenues in the following regions are those that are attributable to the individual countries within the region to which the product was shipped (in thousands): | |||||||||
For the Three Months Ended | |||||||||
March 31, | |||||||||
2014 | 2013 | ||||||||
North America | $ | 1,349 | $ | 1,018 | |||||
Asia | 178 | 127 | |||||||
Europe | 109 | 111 | |||||||
All other regions | 13 | 29 | |||||||
Total | $ | 1,649 | $ | 1,285 | |||||
Organization_and_Significant_A3
Organization and Significant Accounting Policies - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | 3 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | ||||||||||||||||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 12, 2013 | Jan. 22, 2013 | Jul. 01, 2006 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | 2-May-14 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 11, 2013 | 2-May-14 | |
Research and Development [Member] | Research and Development [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Warrants [Member] | Warrants [Member] | Skin Care [Member] | Skin Care [Member] | Cell Technology [Member] | Cell Technology [Member] | Subsequent Event [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | ||||||||
Common Stock Purchase Agreement [Member] | Subsequent Event [Member] | |||||||||||||||||||||||
Common Stock Purchase Agreement [Member] | ||||||||||||||||||||||||
Item Effected [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of ownership in issued and outstanding shares of common stock parent Company | 93.70% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock in subsidiary Company | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Burn rate | $677,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Capital expenditures and patent costs | 52,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Potential common stock value to be sold | ' | ' | 10,250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,250,000 | ' |
Total number of shares of common stock sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,200,000 | 5,200,000 | 6,866,666 | 1,666,666 | 2,200,000 |
Common stock sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 360,000 | 1,104,000 | 1,354,000 | 250,000 | 360,000 |
Revenues | 1,649,000 | 1,285,000 | 6,147,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted cash | 50,000 | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Allowance for doubtful accounts | 19,000 | ' | 19,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated useful life of property and equipment | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Patents and patent licenses | 2,867,000 | ' | 2,760,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amortization expense | ' | ' | ' | ' | ' | ' | ' | 15,000 | 15,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated amortization | 525,000 | ' | 510,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of revenue contributed | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 49.00% | 51.00% | 51.00% | 49.00% | ' | ' | ' | ' | ' |
Rate of return under 30-day product guarantee | ' | ' | 3.00% | 3.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Period of right of return guarantee | ' | ' | '30 days | '30 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Allowance for sales returns | 10,000 | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net deferred revenue | $0 | ' | $3,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Non-vested stock options outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | 552,625 | 145,000 | 822,500 | 335,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Vested stock options outstanding | 19,431,138 | 15,864,448 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options outstanding, non-vested | 3,848,655 | 6,811,745 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants outstanding convertible into common stock | 45,650,654 | 9,462,500 | ' | ' | 2,500,000 | 5,062,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants outstanding | 200,000 | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44,983,988 | 9,462,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Organization_and_Significant_A4
Organization and Significant Accounting Policies - Fair Values of Assets and Liabilities (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
ASSETS: | ' | ' |
Cash equivalents | $5 | $5 |
LIABILITIES: | ' | ' |
Warrants to purchase common stock | 4,302 | 4,925 |
Level 1 [Member] | ' | ' |
ASSETS: | ' | ' |
Cash equivalents | 5 | 5 |
LIABILITIES: | ' | ' |
Warrants to purchase common stock | ' | ' |
Level 2 [Member] | ' | ' |
ASSETS: | ' | ' |
Cash equivalents | ' | ' |
LIABILITIES: | ' | ' |
Warrants to purchase common stock | ' | ' |
Level 3 [Member] | ' | ' |
ASSETS: | ' | ' |
Cash equivalents | ' | ' |
LIABILITIES: | ' | ' |
Warrants to purchase common stock | $4,302 | $4,925 |
Organization_and_Significant_A5
Organization and Significant Accounting Policies - Fair Value Measurement and Unobservable Rollforward Activity of Liabilities (Detail) (USD $) | 3 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 |
Fair Value Disclosures [Abstract] | ' | ' |
Beginning balance | $4,925 | ' |
Issuances of warrants | ' | 5,986 |
Exercise of warrants | ' | -1,815 |
Adjustments to estimated fair value | -623 | 754 |
Ending balance | $4,302 | $4,925 |
Inventory_Summary_of_the_Compo
Inventory - Summary of the Components of Inventories (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ' | ' |
Raw materials | $178 | $147 |
Work in process | 397 | 446 |
Finished goods | 912 | 902 |
Total | 1,487 | 1,495 |
Less: allowance for inventory obsolescence | -130 | -126 |
Inventory, net | $1,357 | $1,369 |
Property_and_Equipment_Summary
Property and Equipment - Summary of Property and Equipment (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | $2,377 | $2,364 |
Less: accumulated depreciation and amortization | -1,635 | -1,534 |
Property and equipment, net | 742 | 830 |
Machinery and Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | 1,178 | 1,170 |
Computer Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | 249 | 246 |
Office Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | 205 | 203 |
Leasehold Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | $745 | $745 |
Property_and_Equipment_Additio
Property and Equipment - Additional Information (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Property Plant And Equipment [Abstract] | ' | ' |
Depreciation expense | $101,000 | $101,000 |
Patent_Licenses_Additional_Inf
Patent Licenses - Additional Information (Detail) (USD $) | 0 Months Ended | 3 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | ||||
14-May-04 | Feb. 13, 2004 | Dec. 31, 2003 | Mar. 31, 2014 | Feb. 07, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Feb. 07, 2013 | Feb. 07, 2013 | Mar. 31, 2014 | |
UMass IP [Member] | UMass IP [Member] | UMass IP [Member] | UMass IP [Member] | UMass IP [Member] | ACT IP [Member] | |||||
Installment | Minimum [Member] | Maximum [Member] | ||||||||
Patent Licenses [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
License fees | ' | ' | $340,000 | ' | ' | $75,000 | $150,000 | ' | ' | ' |
Additional option fees | ' | 22,500 | ' | ' | ' | ' | ' | ' | ' | ' |
Additional license fees | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Obligation to pay royalties (Ranged) | ' | ' | ' | ' | ' | ' | ' | 6.00% | 12.00% | ' |
Royalties percentage of net sales | ' | ' | ' | ' | 0.25% | ' | ' | ' | ' | ' |
Number of installments | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' |
Patent acquisition costs | ' | ' | ' | $2,078,000 | ' | ' | ' | ' | ' | $747,000 |
Patent_Licenses_Summary_of_Fut
Patent Licenses - Summary of Future Amortization Expense Related to Intangible Assets Subject to Amortization (Detail) (USD $) | Mar. 31, 2014 |
In Thousands, unless otherwise specified | |
Goodwill And Intangible Assets Disclosure [Abstract] | ' |
2014 (remaining nine months) | $48 |
2015 | 63 |
2016 | 64 |
2017 | 64 |
2018 | 64 |
Thereafter | 2,018 |
Total | $2,321 |
Advances_Additional_Informatio
Advances - Additional Information (Detail) (USD $) | Mar. 31, 2014 | Jun. 18, 2008 |
Advances [Abstract] | ' | ' |
Advances from nonaffiliated collaboration | ' | $250,000 |
Specified amount of revenue to be utilized for advances | ' | 250,000 |
Revenue realized from agreement | $0 | ' |
Advances_Schedule_of_Advances_
Advances - Schedule of Advances from Nonaffiliated Collaboration (Detail) (USD $) | Jun. 18, 2008 | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | BioTime, Inc. [Member] | BioTime, Inc. [Member] | |
Advances [Line Items] | ' | ' | ' |
Advances from nonaffiliated collaboration | $250 | $250 | $250 |
Capital_Stock_Additional_Infor
Capital Stock - Additional Information (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 19, 2013 |
Equity [Abstract] | ' | ' | ' |
Common stock, shares authorized | 300,000,000 | 300,000,000 | ' |
Preferred stock, shares authorized | 20,000,000 | ' | ' |
Common stock, par value | $0.00 | $0.00 | $0.00 |
Preferred stock, par value | $0.00 | ' | ' |
Capital_Stock_Series_B_Preferr
Capital Stock - Series B Preferred Stock Transactions - Additional Information (Detail) (USD $) | 0 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | |||||||
12-May-08 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 19, 2013 | 12-May-08 | Mar. 31, 2013 | 12-May-08 | Dec. 31, 2013 | Sep. 30, 2013 | Mar. 31, 2013 | 31-May-08 | Mar. 31, 2014 | 12-May-08 | |
Investor | Series B Warrants [Member] | Series B Warrants [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | ||||
Common Stock [Member] | |||||||||||||
Class of Stock [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of accredited investors | 5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total number of common stock sold | ' | ' | ' | ' | ' | ' | 400,000 | ' | ' | ' | ' | ' | ' |
Number of Series B Preferred Stock for each Series B unit | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' |
Number of warrants to purchase common stock | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, par value | ' | $0.00 | $0.00 | $0.00 | ' | ' | $1 | ' | ' | ' | ' | ' | ' |
Proceeds from issuance of preferred stock | ' | ' | ' | ' | ' | ' | $400,000 | ' | ' | ' | ' | ' | ' |
Conversion ratio for each share | ' | ' | ' | ' | ' | 0.2 | ' | ' | ' | ' | ' | ' | 2 |
Warrants exercisable | ' | ' | ' | ' | ' | ' | $0.50 | ' | ' | ' | ' | ' | ' |
Initial conversion price | ' | ' | ' | ' | ' | ' | $0.50 | ' | ' | ' | ' | ' | ' |
Number of years from issuance of warrants to convert as common stock | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' |
Common stock issued upon conversion, conversion price per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.20 | ' | ' | ' |
Convertible preferred stock, conversion price | ' | ' | ' | ' | ' | ' | ' | $0.15 | $0.15 | ' | ' | ' | ' |
Liquidation premium | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6.00% | ' | ' |
Preferred stock, shares issued | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' | ' | ' | 300,000 | ' |
Preferred stock, shares outstanding | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' | ' | ' | 300,000 | ' |
Capital_Stock_Series_C_Preferr
Capital Stock - Series C Preferred Stock Transactions - Additional Information (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Jan. 22, 2013 | Sep. 23, 2008 | Aug. 20, 2008 | Jan. 22, 2013 |
Series C Preferred Stock [Member] | Series C Preferred Stock [Member] | Series C Preferred Stock [Member] | Series C Preferred Stock [Member] | Series C Preferred Stock [Member] | Common Stock [Member] | |
Class of Stock [Line Items] | ' | ' | ' | ' | ' | ' |
Number of preferred stock sold | ' | ' | ' | 1,300,000 | 700,000 | ' |
Convertible shares of common stock | ' | ' | $0.25 | $1 | $0.25 | ' |
Preferred stock, shares issued | 0 | 0 | ' | ' | ' | ' |
Preferred stock, shares outstanding | 0 | 0 | ' | ' | ' | ' |
Conversion of convertible shares | ' | ' | ' | ' | ' | 8,000,000 |
Capital_Stock_Series_D_Preferr
Capital Stock - Series D Preferred Stock Transactions - Additional Information (Detail) (Series D Preferred Stock [Member], USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | |
Dec. 30, 2008 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | |
Class of Stock [Line Items] | ' | ' | ' | ' |
Preferred stock, shares issued | 43 | 43 | ' | 43 |
Total proceeds | $4,700,000 | ' | ' | ' |
Preferred stock, price per share | $100,000 | ' | ' | ' |
Preferred stock, shares outstanding | ' | 43 | ' | 43 |
Common stock issued upon conversion, conversion price per share | ' | $0.15 | $0.20 | $0.15 |
X-Master Inc. [Member] | ' | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' | ' |
Preferred stock, shares issued | ' | 10 | ' | ' |
Dr. Andrey Semechkin [Member] | ' | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' | ' |
Preferred stock, shares issued | ' | 33 | ' | ' |
Capital_Stock_Series_G_Preferr
Capital Stock - Series G Preferred Stock Transactions - Additional Information (Detail) (Series G Preferred Stock [Member], USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | ||
Mar. 09, 2012 | Mar. 31, 2014 | Sep. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2013 | |
Directors | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | ' | ' | ' | ' | ' |
Convertible shares of common stock | $0.40 | ' | ' | ' | ' |
Initial conversion ratio of common stock | ' | 2.5 | ' | ' | ' |
Preferred stock, shares outstanding | ' | 5,000,000 | ' | ' | 5,000,000 |
Number of directors to be nominated by preferred shareholders | 2 | ' | ' | ' | ' |
Number of independent directors out of directors to be nominated by preferred shareholders | 1 | ' | ' | ' | ' |
Legal costs | $59,000 | ' | ' | ' | ' |
Preferred stock, shares issued | ' | 5,000,000 | ' | ' | 5,000,000 |
Common stock issued upon conversion, conversion price per share | ' | ' | ' | $0.20 | $0.15 |
Convertible preferred stock, conversion price | ' | $0.30 | $0.30 | $0.37 | $0.30 |
Convertible preferred stock conversion ratio | ' | 3.31 | 3.28 | 2.67 | 3.291 |
Minimum [Member] | ' | ' | ' | ' | ' |
Changes In Equity And Comprehensive Income Line Items [Line Items] | ' | ' | ' | ' | ' |
Common stock issued upon conversion, conversion price per share | ' | $0.18 | ' | ' | ' |
Minimum [Member] | Director [Member] | ' | ' | ' | ' | ' |
Changes In Equity And Comprehensive Income Line Items [Line Items] | ' | ' | ' | ' | ' |
Preferred stock, shares outstanding | 1,000,000 | ' | ' | ' | ' |
Maximum [Member] | ' | ' | ' | ' | ' |
Changes In Equity And Comprehensive Income Line Items [Line Items] | ' | ' | ' | ' | ' |
Common stock issued upon conversion, conversion price per share | ' | $0.22 | ' | ' | ' |
AR Partners, LLC [Member] | ' | ' | ' | ' | ' |
Changes In Equity And Comprehensive Income Line Items [Line Items] | ' | ' | ' | ' | ' |
Number of purchase agreement shares sold | 5,000,000 | ' | ' | ' | ' |
Selling price per share | $1 | ' | ' | ' | ' |
Common stock sold | $5,000,000 | ' | ' | ' | ' |
Capital_Stock_Common_Stock_Pur
Capital Stock - Common Stock Purchase Agreement Transactions and Others - Additional Information (Detail) (USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 0 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | |||||||||||||||||||||||||||
Jul. 19, 2013 | Mar. 12, 2013 | Jan. 22, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | 2-May-14 | Mar. 31, 2014 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 12, 2013 | Jan. 22, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 11, 2013 | 2-May-14 | Dec. 09, 2010 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Jul. 24, 2013 | Dec. 31, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | Oct. 24, 2013 | Oct. 24, 2013 | Jul. 24, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 19, 2013 | Dec. 31, 2013 | Jul. 24, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 31, 2013 | Jul. 19, 2013 | Jul. 24, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | |
Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Placement Agent Warrants [Member] | Placement Agent Warrants [Member] | Placement Agent Warrants [Member] | Co-Chairman and Chief Executive Officer [Member] | Co-Chairman and Chief Executive Officer [Member] | Dr. Andrey Semechkin and Ruslan Semechkin [Member] | Dr. Andrey Semechkin and Ruslan Semechkin [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Aspire Capital Fund, LLC [Member] | Aspire Capital Fund, LLC [Member] | Aspire Capital Fund, LLC [Member] | Limit One [Member] | Limit Two [Member] | Limit Three [Member] | Minimum [Member] | Units [Member] | Units [Member] | Units [Member] | Units [Member] | Units [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Common Stock [Member] | Common Stock [Member] | Units and Series B Warrants [Member] | |||||||
Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | Registration Rights [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Subscription Agreements [Member] | Co-Chairman and Chief Executive Officer [Member] | Company's Chief Scientific Officer [Member] | Adjusted [Member] | Subscription Agreements [Member] | Co-Chairman and Chief Executive Officer [Member] | Co-Chairman and Chief Executive Officer [Member] | Co-Chairman and Chief Executive Officer [Member] | Company's Chief Scientific Officer [Member] | Company's Chief Scientific Officer [Member] | Company's Chief Scientific Officer [Member] | Dr. Andrey Semechkin and Ruslan Semechkin [Member] | Subscription Agreements [Member] | Subscription Agreements [Member] | Subscription Agreements [Member] | |||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | Subscription Agreements [Member] | Subscription Agreements [Member] | Subscription Agreements [Member] | Subscription Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, share issued | ' | 5,000,000 | 10,125,000 | 156,904,553 | ' | 151,175,053 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' |
Common stock value per share | ' | $0.20 | $0.20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock value | ' | $1,000,000 | $2,025,000 | $157,000 | ' | $151,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $25,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of warrant period from which warrants exercisable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Warrants to common stock purchased | ' | 50.00% | 50.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares into which warrants convertible | ' | 2,500,000 | 5,062,500 | 45,650,654 | 9,462,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants exercise price | ' | 0.2 | 0.2 | ' | ' | ' | ' | ' | 0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.15 | ' | ' | ' | 0.15 | 0.15 | ' | ' | ' |
Sale and issuance of Units | ' | ' | ' | ' | ' | ' | 2,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | 5,200,000 | 6,866,666 | 1,666,666 | 2,200,000 | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares/warrants included in total additional units | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,998,999 | 667,667 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | 16,754,822 | ' | 20,000,000 | 20,000,000 | 20,000,000 | ' |
Common stock, par value | $0.00 | ' | ' | $0.00 | ' | $0.00 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of warrants issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gross proceeds from sale of units | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 |
Warrant issued | ' | ' | ' | ' | ' | 64,983,988 | ' | ' | 666,666 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,998,999 | ' | ' | 667,667 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from stock offering | 2,377,000 | ' | ' | 1,104,000 | 3,289,000 | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | 497,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 497,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of agent fee on gross proceeds from Offering | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum amount of reimbursement payable to agent | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 75,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of agent warrants to purchase on units issued in offering | ' | ' | ' | ' | ' | ' | ' | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants, term | ' | ' | ' | '5 years | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' |
Percentage of Agent cash solicitation fee on gross proceeds | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Series B warrants issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants exercise price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | $0.15 | ' | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expiration date of warrants | ' | ' | ' | ' | ' | 24-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 24-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from issuance of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,356,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of warrants exercised | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,304,822 | ' | ' | ' | 0 | 16,754,822 | 4,450,000 | ' | 2,754,821 | 2,754,821 | ' | 667,667 | 667,667 | ' | ' | ' | ' | 0 | 200,000 | ' | ' | ' | ' | ' |
Adjusted exercise price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds form warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,722,000 | ' | ' | ' | ' | ' | 634,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30,000 | ' | ' | ' | ' | ' |
Number of additional shares/warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,754,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants expired unexercised | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,245,178 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock reserved for future issuance | ' | ' | ' | 37,888,154 | ' | 37,888,154 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 36,554,822 | 36,554,822 | ' | ' | ' | ' | ' |
Warrants outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | 666,666 | 666,666 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Potential common stock value to be sold | ' | ' | ' | ' | ' | 10,250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock sold | ' | ' | ' | ' | ' | ' | 360,000 | ' | ' | ' | ' | ' | ' | ' | ' | 1,104,000 | 1,354,000 | 250,000 | 360,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash fee paid for commitment to purchase additional shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 155,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of common stock to be sold | ' | ' | ' | ' | ' | ' | ' | 13,133,334 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Potential common stock value to be sold | ' | ' | ' | ' | ' | ' | ' | 8,896,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common shares authorized to purchase | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | 300,000 | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Closing price of common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.05 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock value under stock purchase agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Purchase agreement expired | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 31-Dec-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock purchase agreement period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issued shares to aspire capital for operating activities | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issued to aspire capital for operating activities | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $264,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Capital_Stock_Summary_of_Share
Capital Stock - Summary of Shares of Common Stock Reserved for Future Issuance (Detail) | Mar. 31, 2014 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Shares of common stock reserved for future issuance net | 128,835,341 |
Options Outstanding [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Shares of common stock reserved for future issuance net | 23,279,793 |
Options Available for Future Grant [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Shares of common stock reserved for future issuance net | 12,621,950 |
Convertible Preferred Stock [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Shares of common stock reserved for future issuance net | 47,282,944 |
Warrants [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Shares of common stock reserved for future issuance net | 45,650,654 |
Related_Party_Transactions_Add
Related Party Transactions - Additional Information (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Related Party Transactions [Abstract] | ' | ' |
Related party rent expense | $35,000 | $28,000 |
Income_Taxes_Additional_Inform
Income Taxes - Additional Information (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Income Tax Disclosure [Abstract] | ' | ' |
Provision for income tax | ' | ' |
Stock_Options_and_Warrants_Add
Stock Options and Warrants - Additional Information (Detail) (USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||
Jul. 24, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2011 | Mar. 12, 2013 | Jan. 22, 2013 | Jul. 24, 2013 | Mar. 31, 2014 | Dec. 31, 2006 | Mar. 31, 2014 | Dec. 31, 2010 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2009 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Jul. 24, 2013 | Dec. 31, 2013 | Jul. 24, 2013 | Jul. 24, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 31, 2013 | Oct. 24, 2013 | Oct. 24, 2013 | Oct. 17, 2013 | Jul. 24, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 12, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2008 | Dec. 31, 2008 | 12-May-08 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2008 | Dec. 31, 2008 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 19, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jul. 24, 2013 | Mar. 31, 2014 | Dec. 31, 2011 | Sep. 30, 2011 | Dec. 31, 2011 | Dec. 31, 2011 | |
Series B Warrants [Member] | 2006 Plan [Member] | 2006 Plan [Member] | 2010 Plan [Member] | 2010 Plan [Member] | Outside Plan [Member] | Outside Plan [Member] | Outside Plan [Member] | 2006 Plan and 2010 Plan [Member] | 2006 Plan and 2010 Plan [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Units [Member] | Units [Member] | Common Stock [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series A Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | U.S. Treasury Notes [Member] | U.S. Treasury Notes [Member] | Co-Chairman and Chief Executive Officer [Member] | Co-Chairman and Chief Executive Officer [Member] | Co-Chairman and Chief Executive Officer [Member] | Company's Chief Scientific Officer [Member] | Company's Chief Scientific Officer [Member] | Dr. Andrey Semechkin and Ruslan Semechkin [Member] | Dr. Andrey Semechkin and Ruslan Semechkin [Member] | Dr. Andrey Semechkin and Ruslan Semechkin [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Warrants [Member] | Warrants [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series-A and Placement Agent Warrants [Member] | Series-A and Placement Agent Warrants [Member] | Placement Agent Warrants [Member] | Placement Agent Warrants [Member] | Placement Agent Warrants [Member] | Placement Agent Warrants [Member] | YKA Loan [Member] | Bio Time [Member] | Bio Time [Member] | Bio Time [Member] | Bio Time [Member] | |||||||||
2006 Plan and 2010 Plan [Member] | Adjusted [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Series B Warrants [Member] | Warrants Issued with Preferred Stock [Member] | Warrants Issued with Preferred Stock [Member] | Warrants Issued with Preferred Stock [Member] | Warrants to Purchase Shares of Common Stock [Member] | Warrants Issued with Preferred Stock [Member] | Warrants Issued with Preferred Stock [Member] | Warrants Issued with Preferred Stock [Member] | Warrants to Purchase Shares of Common Stock [Member] | Warrants [Member] | Tranches | Maximum [Member] | Maximum [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options granted to employees, directors and consultants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000,000 | ' | 18,000,000 | ' | ' | 10,257,593 | ' | 1,491,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 529,500 | ' | 961,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expiry of options | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | '10 years | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options vesting terms | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '50 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' |
Unrecognized compensation expense related to stock options | ' | ' | $1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized compensation cost related to weighted-average period | ' | ' | '1 year 4 months 24 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '9 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Grant-date fair value of restricted stock awards | ' | ' | 29,000 | 41,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation expense | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 39,000 | 68,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized compensation costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 102,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants outstanding | ' | ' | 200,000 | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44,983,988 | 9,462,500 | ' | ' | 0 | 2 | 2,000,000 | ' | ' | ' | 0 | 2 | 1,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares issued | ' | ' | 156,904,553 | ' | 151,175,053 | ' | 5,000,000 | 10,125,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants exercise price | ' | ' | ' | ' | ' | ' | 0.2 | 0.2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.15 | ' | ' | ' | 0.15 | ' | ' | ' | 0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.25 | ' | ' | 0.25 | ' | ' | ' | ' | ' | 0.25 | ' | ' | ' | ' | ' | 0.15 | ' | ' | ' | ' | ' | ' | ' | ' |
Expiry date of warrants | ' | ' | 30-Sep-16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 24-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 31-Jan-13 | ' | ' | ' | ' | ' | 31-Jul-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 31-Aug-13 | ' | ' | ' | ' |
Warrant to purchase common stock | ' | ' | 45,650,654 | 9,462,500 | ' | ' | 2,500,000 | 5,062,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of warrant or right term | ' | ' | '5 years | ' | ' | ' | ' | ' | '65 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' |
Number of warrants hold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale and issuance of Units | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares/warrants included in total additional units | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | 20,000,000 | ' | ' | 16,754,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maturity term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of warrants issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of agent fee on gross proceeds from Offering | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum amount of reimbursement payable to agent | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 75,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants issued | ' | ' | ' | ' | 64,983,988 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 666,666 | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of agent warrants to purchase on units issued in offering | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Agent cash solicitation fee on gross proceeds | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants exercise price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | $0.15 | ' | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Closing bid price of common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 80.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants expiration date | ' | ' | ' | ' | ' | ' | ' | ' | 24-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock price | ' | ' | $0.19 | ' | $0.21 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrant exercise price | ' | ' | $0.15 | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock price volatility | ' | ' | 83.90% | ' | 84.30% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Risk free interest rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.45% | 1.55% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options and warrant expected term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '4 years 3 months 26 days | '4 years 6 months 22 days | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants description | ' | ' | 'Monte-Carlo simulation model | ' | 'Monte-Carlo simulation model | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expected dividend payout | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | 0.00% | ' | ' | ' | ' | ' | ' |
Fair value of warrant liability in excess of proceeds | 1,390,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value of warrants at issuance | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,725,000 | ' | ' | ' | ' | ' | ' | ' | 2,645,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 115,000 | ' | ' | ' | ' | ' |
Warrant liabilities | 4,485,000 | ' | 4,302,000 | ' | 4,925,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in fair value of warrants | ' | ' | -623,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 623,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from issuance of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,356,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of warrants exercised | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 200,000 | ' | ' | 12,304,822 | ' | ' | ' | ' | 0 | 16,754,822 | 4,450,000 | ' | ' | ' | 2,754,821 | 2,754,821 | 667,667 | 667,667 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants expiration date | ' | ' | ' | ' | 24-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 24-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of additional shares/warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,754,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from stock offering | ' | 2,377,000 | 1,104,000 | 3,289,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | 497,000 | 497,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds form warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $30,000 | ' | ' | $1,722,000 | ' | ' | ' | ' | ' | ' | $634,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of closing bid price for calculation of exercise price of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Closing bid price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjusted exercise price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants expired unexercised | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,245,178 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock reserved for future issuance | ' | ' | 37,888,154 | ' | 37,888,154 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 36,554,822 | 36,554,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 666,666 | 666,666 | ' | ' | ' | ' | ' | ' |
Additional warrants earned | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of tranches of common stock warrants issuable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' |
Number of shares which can be purchased by the exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' |
Strike prices | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | 1.5 |
Vesting over four quarters | ' | ' | ' | ' | ' | 'Four quarters | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock_Options_and_Warrants_Sch
Stock Options and Warrants - Schedule of Total Stock-Based Compensation Expense (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation expense | $347 | $409 |
Cost of Sales [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation expense | 15 | ' |
Research and Development [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation expense | 70 | 84 |
Selling and Marketing [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation expense | 11 | 9 |
General and Administrative [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation expense | $251 | $316 |
Stock_Options_and_Warrants_Sum
Stock Options and Warrants - Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2009 | Mar. 31, 2014 | Dec. 31, 2013 |
Outside Plan [Member] | Outside Plan [Member] | Outside Plan [Member] | 2006 Plan and 2010 Plan [Member] | 2006 Plan and 2010 Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Shares, Outstanding, Beginning balance | 44,983,988 | 44,983,988 | 3,500,000 | 7,609,293 | 8,254,232 | ' | 16,028,400 | 15,122,900 |
Number of Shares, Granted | ' | ' | ' | ' | ' | 10,257,593 | ' | 1,491,500 |
Number of Shares, Exercised | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Shares, Canceled or expired | ' | ' | ' | ' | -644,939 | ' | -357,900 | -586,000 |
Number of Shares, Outstanding, Ending balance | 44,983,988 | 44,983,988 | 3,500,000 | 7,609,293 | 7,609,293 | ' | 15,670,500 | 16,028,400 |
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance | ' | ' | ' | $0.62 | $0.65 | ' | $1.12 | $1.18 |
Number of Shares, Options vested and expected to vest Ending Balance | ' | ' | ' | ' | ' | ' | 15,387,508 | ' |
Weighted Average Exercise Price Per Share, Granted | ' | ' | ' | ' | ' | ' | ' | $0.26 |
Number of Shares, Options exercisable Ending Balance | ' | ' | ' | ' | ' | ' | 11,821,845 | ' |
Weighted Average Exercise Price Per Share, Exercised | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted Average Exercise Price Per Share, Canceled or expired | ' | ' | ' | ' | $1 | ' | $0.76 | $0.61 |
Weighted Average Exercise Price Per Share, vested and exercisable Ending balance | ' | ' | ' | $0.62 | $0.62 | ' | $1.13 | $1.12 |
Weighted Average Exercise Price, Options vested or expected to vest Ending Balance | ' | ' | ' | ' | ' | ' | $1.14 | ' |
Weighted Average Exercise Price, Options exercisable Ending Balance | ' | ' | ' | ' | ' | ' | $1.21 | ' |
Weighted Average Remaining Contractual Term, Options Outstanding Ending Balance | ' | ' | ' | ' | ' | ' | '6 years 2 months 12 days | ' |
Weighted Average Remaining Contractual Term, Options vested or expected to vest Ending Balance | ' | ' | ' | '5 years 7 months 6 days | ' | ' | '6 years 1 month 6 days | ' |
Weighted Average Remaining Contractual Term, Options exercisable Ending Balance | ' | ' | ' | ' | ' | ' | '5 years 7 months 6 days | ' |
Aggregate Intrinsic Value, Options outstanding, Ending balance | ' | ' | ' | ' | ' | ' | $1 | ' |
Aggregate Intrinsic Value, Options vested or expected to vest Ending Balance | ' | ' | ' | ' | ' | ' | 1 | ' |
Aggregate Intrinsic Value, Options exercisable Ending Balance | ' | ' | ' | ' | ' | ' | ' | ' |
Stock_Options_and_Warrants_Sum1
Stock Options and Warrants - Summary of Changes in Restricted Stock Award Activity (Detail) (Restricted Stock [Member], USD $) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | |
Restricted Stock [Member] | ' | ' | ' |
Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Line Items] | ' | ' | ' |
Number of Shares, Unvested, Beginning balance | 145,000 | 335,000 | 822,500 |
Number of Shares, Granted | 529,500 | 961,000 | ' |
Number of Shares, Vested | -121,875 | -1,029,750 | ' |
Number of Shares, Forfeited | ' | -121,250 | ' |
Number of Shares, Unvested, Ending balance | 552,625 | 145,000 | 822,500 |
Weighted Average Grant Date Fair Value, Unvested, Beginning balance | $0.23 | $0.32 | ' |
Weighted Average Grant Date Fair Value, Granted | $0.24 | $0.24 | ' |
Weighted Average Grant Date Fair Value, Vested | $0.24 | $0.27 | ' |
Weighted Average Grant Date Fair Value, Forfeited | ' | $0.25 | ' |
Weighted Average Grant Date Fair Value, Unvested, Ending balance | $0.24 | $0.23 | ' |
Stock_Options_and_Warrants_Sum2
Stock Options and Warrants - Summary of Outstanding Warrants Related to Warrant Transactions (Detail) (USD $) | 3 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||
Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | |
Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | Series A Common Stock [Member] | Series A Common Stock [Member] | Series B Common Stock [Member] | Series B Common Stock [Member] | Placement Agent [Member] | Placement Agent [Member] | YKA Loan [Member] | YKA Loan [Member] | Skin Care Marketing [Member] | Skin Care Marketing [Member] | Skin Care Marketing [Member] | Jan 2013 Financing [Member] | Jan 2013 Financing [Member] | Mar 2013 Financing [Member] | Mar 2013 Financing [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Shares, Outstanding, Beginning balance | 44,983,988 | 3,500,000 | 1,600,000 | ' | 300,000 | ' | ' | 36,554,822 | ' | ' | ' | 666,666 | 1,400,000 | ' | 200,000 | 200,000 | 200,000 | ' | 5,062,500 | ' | 2,500,000 | ' | ' | ' | ' |
Warrants, Issued | ' | 64,983,988 | ' | ' | ' | ' | 36,754,822 | ' | 20,000,000 | ' | 666,666 | ' | ' | ' | ' | ' | ' | 5,062,500 | ' | 2,500,000 | ' | ' | ' | ' | ' |
Warrants, Exercised | ' | -16,954,822 | ' | ' | ' | ' | -200,000 | ' | -16,754,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants, Forfeited/Cancelled | ' | -6,545,178 | -1,600,000 | ' | -300,000 | ' | ' | ' | -3,245,178 | ' | ' | ' | -1,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Shares, Outstanding, Ending balance | 44,983,988 | 44,983,988 | ' | ' | ' | ' | 36,554,822 | 36,554,822 | ' | ' | 666,666 | 666,666 | ' | ' | 200,000 | 200,000 | 200,000 | 5,062,500 | 5,062,500 | 2,500,000 | 2,500,000 | ' | ' | ' | ' |
Weighted Average Exercise Price, Outstanding, Beginning balance | $0.17 | $0.34 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.25 | $0.14 | $2 | $2 |
Weighted Average Exercise Price, Issued | ' | $0.16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | ' | $0.20 | ' |
Weighted Average Exercise Price, Exercised | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.14 | ' | $0.15 | ' |
Weighted Average Exercise Price, Forfeited/Cancelled | ' | $0.20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | ' | $0.25 | ' |
Weighted Average Exercise Price, Outstanding, Ending balance | $0.17 | $0.17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.14 | $0.14 | $2 | $2 |
Commitments_and_Contingencies_1
Commitments and Contingencies - Additional Information (Detail) (USD $) | 3 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||
Mar. 31, 2014 | Mar. 31, 2013 | Sep. 30, 2011 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Jul. 31, 2012 | Mar. 31, 2014 | Mar. 31, 2014 | Jan. 02, 2013 | Jul. 01, 2011 | Mar. 31, 2014 | |
Skin Care [Member] | Skin Care [Member] | Skin Care [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Oceanside [Member] | Priestly Drive [Member] | Priestly Drive [Member] | Priestly Drive [Member] | Frederick [Member] | |||
Tranches | Customer [Member] | Customer [Member] | Other Customer [Member] | Skin Care [Member] | sqft | sqft | sqft | sqft | sqft | |||||
Commitments And Contingencies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Current square feet of leased office and laboratory | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,215 | ' | ' | ' | ' |
Current base rent | ' | ' | ' | ' | ' | ' | ' | ' | ' | $8,588 | $11,837 | ' | ' | $11,644 |
Expiry of lease | ' | ' | ' | ' | ' | ' | ' | ' | ' | '2016-08 | ' | ' | ' | ' |
Percentage of increase in monthly base rent | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.00% | 3.00% | ' | ' | ' |
Expiry of Lease | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 29-Feb-16 | ' | ' | 31-Dec-15 |
Expiry of lease additional | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | '5 years |
Area of manufacturing facility given on lease | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,848 | 8,199 | 5,520 |
Initial square feet of leased office and laboratory | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,653 | ' | ' | ' |
Initial monthly base rent | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,118 | ' | ' | ' |
Rent expense | 79,000 | 74,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of net revenues for Direct Sales generated from the proprietary mailings | ' | ' | 20.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of net revenues for Referral Sales | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Termination of the agreement | ' | ' | '30 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Tranches of common stock | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock warrants to be issued for the benefit of the third party marketing organization | ' | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Strike prices, tranche one | ' | ' | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Strike prices, tranche two | ' | ' | $2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrant term | '5 years | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Commission percentage on direct sale | ' | ' | ' | ' | ' | ' | ' | ' | 18.00% | ' | ' | ' | ' | ' |
Percentage on net revenue derived from referral sales | ' | ' | ' | ' | ' | ' | ' | ' | 9.00% | ' | ' | ' | ' | ' |
Commission expenses | ' | ' | ' | $13,000 | $24,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of revenue | ' | ' | ' | ' | ' | 20.00% | 16.00% | 10.00% | ' | ' | ' | ' | ' | ' |
Commitments_and_Contingencies_2
Commitments and Contingencies - Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) (USD $) | Mar. 31, 2014 |
In Thousands, unless otherwise specified | |
Commitments And Contingencies Disclosure [Abstract] | ' |
2014 (remaining nine months) | $291 |
2015 | 397 |
2016 | 101 |
2017 | 3 |
Total | $792 |
Segments_and_Geographic_Inform2
Segments and Geographic Information - Additional Information (Detail) | 3 Months Ended |
Mar. 31, 2014 | |
Product | |
Subsidiary | |
Segment | |
Segment Reporting [Abstract] | ' |
Number reporting segments | 3 |
Number of wholly-owned subsidiaries | 2 |
Human cell culture products | 130 |
Segments_and_Geographic_Inform3
Segments and Geographic Information - Revenues, Expenses and Operating Income (Loss) by Market Segment (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 |
Revenues: | ' | ' | ' |
Total revenues | $1,649 | $1,285 | $6,147 |
Total operating income (loss) | -2,065 | -1,713 | ' |
Operating expenses: | ' | ' | ' |
Total operating expenses | 3,714 | 2,998 | ' |
Operating income (loss): | ' | ' | ' |
Total revenues | 1,649 | 1,285 | 6,147 |
Total operating income (loss) | -2,065 | -1,713 | ' |
Cosmeceutical Market [Member] | ' | ' | ' |
Revenues: | ' | ' | ' |
Total revenues | 803 | 650 | ' |
Total operating income (loss) | 15 | 47 | ' |
Operating expenses: | ' | ' | ' |
Total operating expenses | 788 | 603 | ' |
Operating income (loss): | ' | ' | ' |
Total revenues | 803 | 650 | ' |
Total operating income (loss) | 15 | 47 | ' |
Biomedical Market [Member] | ' | ' | ' |
Revenues: | ' | ' | ' |
Total revenues | 846 | 635 | ' |
Total operating income (loss) | 140 | 81 | ' |
Operating expenses: | ' | ' | ' |
Total operating expenses | 706 | 554 | ' |
Operating income (loss): | ' | ' | ' |
Total revenues | 846 | 635 | ' |
Total operating income (loss) | 140 | 81 | ' |
Therapeutic Market [Member] | ' | ' | ' |
Revenues: | ' | ' | ' |
Total operating income (loss) | -2,220 | -1,841 | ' |
Operating expenses: | ' | ' | ' |
Total operating expenses | 2,220 | 1,841 | ' |
Operating income (loss): | ' | ' | ' |
Total operating income (loss) | ($2,220) | ($1,841) | ' |
Segments_and_Geographic_Inform4
Segments and Geographic Information - Summary of Significant Revenues in Following Regions (Detail) (USD $) | 3 Months Ended | 12 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 |
Segment Reporting Information [Line Items] | ' | ' | ' |
Total revenue | $1,649 | $1,285 | $6,147 |
North America [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Total revenue | 1,349 | 1,018 | ' |
Asia [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Total revenue | 178 | 127 | ' |
Europe [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Total revenue | 109 | 111 | ' |
All Other Regions [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Total revenue | $13 | $29 | ' |
Subsequent_Events_Additional_I
Subsequent Events - Additional Information (Detail) (USD $) | 12 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | ||
Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 11, 2013 | 2-May-14 | 2-May-14 | |
Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Lincoln Park Capital Fund, LLC [Member] | Subsequent Event [Member] | Subsequent Event [Member] | ||
Common Stock Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | |||||
Common Stock Purchase Agreement [Member] | ||||||
Subsequent Event [Line Items] | ' | ' | ' | ' | ' | ' |
Potential common stock value to be sold | $10,250,000 | ' | ' | $10,250,000 | ' | ' |
Total number of shares of common stock sold | ' | 5,200,000 | 6,866,666 | 1,666,666 | 2,200,000 | 2,200,000 |
Common stock sold | ' | $1,104,000 | $1,354,000 | $250,000 | $360,000 | $360,000 |